

Metabolic screening in newborn


Ali Talea



Pediatric Endocrinologist

Metabolic Disorders Research Center

Molecular-cellular Endocrinology
& Metabolism Research Institute

Tehran University of Medical Sciences





- the generation of any laboratory test result consists of **9 steps**, including :
 - ordering
 - collection
 - identification (at several stages),
 - transportation
 - separation (or preparation)
 - analysis
 - reporting
 - interpretation
 - action

Non IEM

- There are a range of non-specific causes which include:
- Major illness e.g. organ failure (disorders associated with liver dysfunction) (ie,PHE AND TYROSINE)
- Transient illness
- Premature – liver maturity
- Diet / feed
- Parenteral nutrition /TPN
- Analytical error – unlikely with triplicate testing
- Contamination of card

Table 50.5 Non-IEM organic acids in urine as well as dietary/drug/bacterial artefacts

| Compound | Condition |
|--|--|
| Aromatic acids (4-hydroxyphenyl) | Gut bacterial action |
| Mandelic acid | Albumin infusion |
| D-Lactic acid | Short bowel syndrome |
| D-2-Hydroxyisocaproic acid | Short bowel syndrome |
| D-Phenyllactic acid | Short bowel syndrome |
| 3-Hydroxyisovaleric acid | Valproate medication |
| Glutaric acid | Gut bacterial action |
| 3-Hydroxypropionic acid | Gut bacterial action |
| Methylmalonic acid | Vitamin B ₁₂ deficiency |
| Ethylmalonic acid | Vitamin B ₂ deficiency |
| C ₁₀ >C ₈ >C ₆ dicarboxylic acids | MCT diet |
| 7-Hydroxyoctanoic acid | MCT diet |
| 3-Hydroxydicarboxylic acids | Celiac disease |
| Succinic acid | 2-Ketoglutarate decomposition. |
| Glycolic acid | Ethylene glycol poisoning |
| Pyroglutamic acid | Glutamine decomposition Flucloxacillin toxicity |
| Di-(2-ethylhexyl)phthalate | Nutramigen feeding Pregestimil feeding |
| Furane-2,5-dicarboxylic acid | Heated sugars |
| Furoylglycine | Heated sugars |
| 4-Hydroxycyclohexanecarboxylic acid | Food processing |
| Homovanillic acid | Neuroblastoma |
| Vanilmandelic acid | Neuroblastoma, pheochromocytoma |
| N-Acetyltyrosine | Parenteral feeding |
| 5-Hydroxyindoleacetic acid | Carcinoid syndrome |
| Valproate metabolites | Depakine therapy |
| 2-Hydroxyhippuric acid | Salicylate ingestion |
| Ethosuximide metabolites | Antiepileptic therapy |
| Keppra metabolites | Antiepileptic therapy |
| Phenytoin metabolites | Antiepileptic therapy |

- **Cut off:** Gray zone /pathologic zone
- Importance low or high metabolite
- Common metabolite in several diseases specific cut off for each disease
- History clinical status
Diet/Formula/medication/Transfusion
- Metabolite base/enzymology(Enzyme assay)
- If initial result is an alert, or abnormal results are obtained on **two different** NBS specimens, further testing is recommended to establish diagnosis

Definition and Use of Primary and Secondary Markers

- **Primary markers (analytes)** – used to establish presumptive positives.
- **Secondary markers** – used in conjunction with primary analyte results to assign risk
- Isolated elevations of secondary markers are considered unimportant

Secondary metabolites and criteria for mild elevation of primary marker

- For **PKU**: PHE/TYR ratio > 3
- For **MSUD**: LEU+ILE and VAL
- For **PA and MMA**: C3/C2 ratio > 0.4
- For **MCAD**: C8/C10 ratio > 3
- For **VLCAD**: C14:1/C12:1 ratio > 3
- For **LCHAD**: C16-OH plus at least one of the following: C18:1-OH, C16, C18:1
- For **CPT-II/CAT**: C16 and C18:1
- No suitable secondary markers for C3-DC, C4, C5, C5-OH, C5-DC

Action taken by co-ordinator

- **Low risk:** contact physician of record, check clinical status of pt., request second blood spot specimen,
 - recommend follow-up testing if symptomatic
- **Moderate risk** (includes **positive test on repeat specimen** from above and/or presence of **secondary markers**): request follow-up testing; recommend referral to regional metabolic center if child symptomatic
- **High risk:** recommend immediate referral to metabolic center, follow-up testing and initiate appropriate therapy regardless of clinical status

Initial laboratory tests

- Blood gases/Ph
- CK
- Glucose
- Electrolytes
- Ammonia
- Lactate
- Renal function tests
- Liver function tests
- Urinalysis
- Basic hematological tests/coagulation studies

Elevated lactate

- Lactate concentration: $\text{mmol/l} = \text{mg/dl} \times 0.11$
- *Normal values: Blood* $< 2.1 \text{ mmol/l}$ ($< 19 \text{ mg/dl}$). *CSF* $< 1.8 \text{ mmol/l}$ ($< 16 \text{ mg/dl}$)
- *Blood sample:* Uncuffed vein (scalp, i.v. line) or artery, relaxed child. Na-fluoride sample tube
- *Alanine* (plasma amino acids) reflects the concentration of pyruvate (and indirectly lactate) but is not affected by cuffing. Normal $< 450 \mu\text{mol/l}$, alanine/lysine ratio < 3 .

- A primary metabolic disorder should be considered if there is no convincing secondary cause such as **shock, asphyxia or cardiac** disease or in particular a **difficult venepuncture**.

Disorders of the respiratory chain or Krebs cycle

Pyruvate dehydrogenase (PDH) or pyruvate carboxylase deficiency.

primary causes:

- Long-chain fatty acid oxidation disorders
- Organic acidurias, disorders of biotin metabolism
- Glycogen storage diseases, gluconeogenesis disorders

Secondary causes

- **Most common:** the use of a tourniquet or difficulty in drawing the blood
- Muscular activity, assisted ventilation, seizures (lactate up to 4–6 mmol/l)
- Severe systemic disease: central and peripheral hypoxia or ischaemia, shock, cardiac failure, cardiomyopathy, liver or renal failure, septicaemia, diabetes mellitus, etc.
- Any severe metabolic disease
- Renal tubular syndrome, hyperchloraemia, urinary tract infection (lactic aciduria)
- Drugs (biguanides); intoxication (e.g. ethanol)
- Consider thiamine deficiency

Lactate

- *Postprandial elevation* of lactate (> 20%) indicate PDH deficiency or respiratory chain defects, respectively.
- ↑ Lactate after glucose challenge is found also in glycogen storage disease types 0, III, VI.
- *Postprandial decline* of lactate indicate glycogen storage disease type I or gluconeogenesis defects.

Pyruvate

- **Indic:** Pyruvate should not be routinely measured as values obtained may be spurious and lactate is the more relevant and reliable test.
- Pyruvate is sometimes used to determine the **lactate/pyruvate ratio (redox state, normal < 20)**
- Never measure pyruvate without lactate
- Method: Photometric
- Normal: Blood: **50–100** $\mu\text{mol/l}$; CSF: **70–140**;
lactate/pyruvate ratio: **< 20** (elevated in respiratory chain disorders, typically normal in PDH deficiency)

| <i>Finding</i> | <i>Indicative of (selection)</i> |
|-------------------------------|--|
| Anaemia (macrocytic) | Disturbances in cobalamin and/or folic acid metabolism |
| Reticulocytosis | Glycolysis defects, disorders of the γ -glutamyl cycle |
| Vacuolised lymphocytes | Lysosomal storage disorders, juvenile NCL |
| ↑ Alkaline phosphatase | Bile acid synthesis defects, hypoparathyroidism |
| ↓ Alkaline phosphatase | Hypophosphatasia |
| ↓ Cholesterol | Sterol synthesis defects, lipoprotein disorders, glycosylation disorders, peroxisomal disorders |
| ↑ Triglycerides | Glycogen storage disorders, lipoprotein disorders |
| ↑ CK | Dystrophinopathies, fatty acid oxidation disorders, glycogen storage disorders, glycolysis disorders, muscle AMP-deaminase deficiency, mitochondrial disorders |
| ↓ Creatinine | Creatine synthesis disorders |
| ↑ α -Fetoprotein (AFP) | Tyrosinaemia type I, hepatoblastoma, neonatal haemochromatosis, viral hepatitis, ataxia telangiectasia |

| | |
|-------------------------|--|
| ↑ Uric acid | Glycogen storage disorders (incl. Fanconi-Bickel disease), fructose intolerance, disorders of purine metabolism, fatty acid oxidation defects, mitochondrial disorders |
| ↓ Uric acid | Disorders of purine metabolism, molybdenum cofactor deficiency |
| ↑ Iron, transferrin | Haemochromatosis, peroxisomal disorders |
| ↑ Copper | Peroxisomal disorders, Wilson disease (urine, liver) |
| ↓ Copper, ceruloplasmin | Wilson disease (serum), Menkes disease, aceruloplasminaemia |
| Hypo(para)thyroidism | Mitochondrial disorders, CDG |
| Low CSF glucose | Glucose transport protein 1 (GLUT1) deficiency |

- *Obtain urine sample:*
- Check colour and odour
- Perform standard test strip analyses (e.g. ketone bodies, glucose, protein; pH > 5 during acidosis
→ (DD: renal tubular acidosis))
- Store urine sample from the acute phase for organic acids or additional metabolic tests
- *If lumbar puncture is performed:* Store CSF (freeze immediately)

Unusual clinical observations

Urine and body odour

| <i>Odour</i> | <i>Substance</i> | <i>Disorder/origin</i> |
|-------------------------|---------------------------------|---|
| Animal-like, mouse-like | Phenylacetate | Untreated phenylketonuria, phenylbutyrate treatment |
| Maple syrup, "Maggi" | Sotolone | Maple syrup urine disease |
| Acrid (sweaty feet) | Isovaleric acid | Isovaleric aciduria, glutaric aciduria II |
| Male cat urine | 3-OH-isovaleric acid | 3-Methylcrotonylglycinuria, multiple carboxylase deficiency |
| Cabbage | 2-OH-butyric acid | Tyrosinaemia type I |
| Rancid butter | 2-Oxo-4-methiolbutyric acid | Tyrosinaemia type I |
| Sulphur | Hydrogen sulphide | Cystinuria |
| | Methionine | Tyrosinaemia type I, cirrhosis |
| Fish-like | Trimethylamine, dimethylglycine | Trimethylaminuria, dimethylglycinuria |

Reducing substances in urine

Method: Test tablets (e.g. Clinitest[®], Bayer)

Detects: Any reducing substances, particularly sugars

| <i>Substance</i> | <i>Disorder/origin</i> |
|----------------------------|---|
| Galactose | Classical galactosaemia, galactokinase deficiency, severe liver disease (secondary galactose intolerance), Fanconi-Bickel disease |
| Fructose | Fructose intolerance, essential fructosuria |
| 4-Hydroxyphenylpyruvate | Tyrosinaemia types I and II |
| Homogentisic acid | Alcaptonuria |
| Xylose, arabinose | Pentosuria, arabinosuria |
| Glucose | Diabetes mellitus, Fanconi syndrome |
| Oxalic acid (massive) | Hyperoxaluria |
| Salicylates, ascorbic acid | Drugs |
| Uric acid | Hyperuricosuria |
| Hippuric acid | Na-benzoate treatment of hyperammonaemia, malabsorption |

Nitroprusside test (Brand reaction)

Method: 0.5 ml urine + 200 µl 5% Na-cyanide

Detects: Sulphur-containing acids (disulphides). False positive result may occur in severe ketosis, may be false negative in homocystinuria (assess total plasma homocysteine!).

| <i>Substance</i> | <i>Disorder/origin</i> |
|------------------|--|
| Cystine | Cystinuria, hyperargininaemia, generalised hyperaminoaciduria |
| Homocystine | Classical homocystinuria, cobalamin deficiencies, cystathioninuria (bacterial in urinary tract infections) |
| Glutathione | Gammaglutamyl transaminase deficiency |
| Drugs | N-Acetylcysteine, penicillamine, captopril, ampicillin and others |

Sulphite test

Method: Dipstick (e.g. Merckoquant® 10013, Merck), *fresh urine at the bedside*

Diagn.: Sulphite oxidase and molybdenum cofactor deficiencies (particularly test early-onset epileptic encephalopathy). Positive result may be caused by various sulphite-containing drugs, false negative results may occur.

Four lab values are important in diagnosis of possible IEM:

A.G > 16: The most specific lab finding suggestive for IEM.

- Anion gap = $[Na^+] - [Cl^- + HCO_3^-]$ 7–16 mmol/l

D.D →

Shock and lactic acidosis

DKA

Renal failure or CMP

2) Ketones:

absence of ketonuria after significant fasting in:



FAOD

Hyperinsulinism

HMGL

Urinary ketones (test strip)

- Ketonuria due to the ketone bodies **3-hydroxybutyrate** and **acetoacetate** is normal during fasting
- pathological in the **fed** state and in the **neonate**
- **Absence of ketones** during fasting is suggestive of a fatty acid oxidation disorder
- Ketosis is a physiological response to **fasting, catabolic state or ketogenic diet**
- **Permanent** ketosis may in rare cases indicate a **ketolysis** defect.
- *Ketosis with fasting hypoglycaemia* indicate adrenal insufficiency or glycogen storage diseases (GSD) type 0.

3) Elevated Ammonia:


Normal range is age dependent:


- **Up to 150 $\mu\text{m/L}$ in premature infant**
- **> 50 $\mu\text{m/L}$ is abnormal in older infant and children**

4) Elevated creatine kinase:

IEM with myopathy or CMP or both, such as:

- **FAOD**
- **Electron transport chain disorders**
- **GSD (specially types III and V)**





- Which diseases are diagnosed by **LC/Mass**
- **a)Diagnostic for:**
- FAOD
- Aminoacidopathies
- UCD
- **b)Suggestive for**
- Organic acidemia
- Mitochondrial disorders
- In suspicion to organic acidemia, differentiation and confirmation by urine **GCMS** is necessary.

- **Diagnosable Components:**

- **LC Mass: 48 Components**

- **GCMS: 135 Components (To 178)**

Newborn Screening: Common Diseases Detected

| | FATTY ACID OXIDATION DISORDERS | ORGANIC ACIDEMIAS | AMINOACIDOPATHIES | UREA CYCLE DISORDERS |
|------------------|---|---|--|---|
| Metabolism | Fat Defect in β -oxidation of fatty acids. | Protein Defect in amino acid breakdown leads to accumulation of organic acid byproducts | Protein Defect in amino acid breakdown leads to accumulation of certain intact amino acids | Protein Defect in making urea (blood urea nitrogen) from ammonia that results from amino acid breakdown |
| Disorders | Medium-chain acyl CoA dehydrogenase Long-chain 3-hydroxy acyl CoA dehydrogenase Very long-chain acyl CoA dehydrogenase | Propionic Methylmalonic Isovaleric | Maple syrup urine Phenylketonuria Homocystinuria tyrosinemia | Ornithine transcarbamylase (X-linked) Citrullinemia Arginosuccinic aciduria |
| Presentation | Hypoketotic Hypoglycemia Lethargy, vomiting Sudden infant death syndrome, Reye syndrome Long-chain disorders have cardiomyopathy and rhabdomyolysis | Metabolic Acidosis With Anion Gap Neonatal lethargy, vomiting, coma, strokes, death | No Acidosis or Hyperammonemia Elevations in specific amino acids See text for clinical features | Hyperammonemia Without Acidosis Neonatal lethargy, vomiting, coma, death |
| Laboratory Tests | Newborn Screen Plasma acylcarnitines Hypoglycemia No or inappropriately low ketones | Newborn Screen Urine organic acids Plasma acylcarnitines | Newborn Screen Plasma amino acids | Newborn Screen (not for ornithine transcarbamylase) Hyperammonemia Plasma amino acids Urine orotic acid |

Expanded NBS – 29 conditions

- 20 inborn errors of metabolism
- 3 hemoglobinopathies
- 2 endocrine disorders
 - Congenital hypothyroidism
 - Congenital adrenal hyperplasia
- 3 other metabolic disorders
 - Cystic fibrosis
 - Galactosemia
 - Biotinidase deficiency
- Hearing loss

The filter papers, Whatman Grade 903 and Ahlstrom Grade 226, are made from high-purity cotton linters and manufactured to yield accurate and reproducible blood samples according to the Clinical and Laboratory Standards Institute's specifications (NBS01-A6)

What are we screening for?

| 9 OA | 5 FAO | 6 AA | 3 Hb Pathies | 6 Others |
|--|--------------------------------------|---|-------------------------------------|---|
| CORE PANEL | | | | |
| IVA GA I HMG MCD MUT 3MCC Cbl A,B PROP BKT | MCAD VLCAD LCHAD TFP CUD | PKU MSUD HCY CIT ASA TYR I | Hb SS Hb S/ β Th Hb S/C | CH BIOT CAH GALT HEAR CF |

| Test | Specimen | Method |
|--|-----------------|---------------|
| Amino Acid & Acylcarnitine Profile | DBS | ESI-MS/MS |
| Amino Acid & Acylcarnitine Profile | Plasma | LC-MS/MS |
| Organic Acid Profile | Urine | GC/MS |
| Single analytes of organic acid (VMA/HVA, Succinyl acetone, Homogentisic, Orotic acid, ...) | Urine | GC/MS |
| Amino Acid Profile | Plasma | HPLC |
| Amino Acid Profile | Urine | HPLC |
| Homocysteine | Plasma | HPLC |

Amino Acid & Acylcarnitine Profile in Plasma




LC-MS/MS



Alanine,
Aspartic Acid,
Arginine,
Citrulline,
Glutamic Acid,
Glycine,
Leucine + Isoleucine,
Methionine,
Ornithine,
Phenylalanine,
Tyrosine,
Valine,
Threonine,
Serine,
Histidine,
Lysine,
Tryptophane,
Proline

Free Carnitine(C0)
Acetylcarnitine(C2) ,
Propionylcarnitine(C3) ,
Malonylcarnitine(C3DC) ,
Butyrylcarnitine(C4)
Hydroxybutyrylcarnitine(C4OH) ,
Ethylmalonylcarnitine(C4DC) ,
Isovalerylcarnitine(C5) ,
Tyglylcarnitine(C5:1) ,
Hydroxyisovalerylcarnitine(C5OH) ,
Glutaryl carnitine(C5DC) ,
Hexanoylcarnitine(C6) ,
HydroxyHexanoylcarnitine(C6OH) ,
Methylglutaryl carnitine(C6DC) ,
Octanoylcarnitine(C8) ,
Decanoylcarnitine(C10) ,
Decenoylcarnitine(C10:1) ,
Dodecanoylcarnitine(C12) ,
Dodecenoylcarnitine(C12:1) ,
Tetradecanoylcarnitine(C14) ,
Tetradecenoylcarnitine(C14:1) ,
Tetradecadienoylcarnitine(C14:2),
Hydroxytetradecanoylcarnitine(C14OH),
Hexadecanoylcarnitine(C16),
Hydroxyhexadecanoylcarnitine(C16OH),
Hexadecenoylcarnitine(C16:1),
Hedroxyhexadecenoylcarnitine(C16:1OH),
Octadecanoylcarnitine(C18),
Octadecenoylcarnitine(C18:1),
Octadecadienoylcarnitine(C18:2),
Hydroxystearoylcarnitine(C18OH),
Hydroxyoctadecenoylcarnitine(C18:1OH),
Hydroxylinoleoylcarnitine(C18:2OH).

Organic Acid Profile





Lactic acid , 2-Hydroxyisobutyric acid , Caproic acid , Glycolic acid , Glyoxylic acid-oxime , Oxalic acid , 2-Hydroxybutyric acid , 3-Hydroxypropionic acid , Pyruvic acid-oxime , Valproic acid , 3-Hydroxybutyric acid , 3-Hydroxyisobutyric acid , 2-Hydroxyisovaleric acid , 2-Methyl-3-hydroxybutyric acid , Malonic acid , 3-Hydroxyisovaleric acid , 2-Keto-isovaleric acid-oxime , Methylmalonic acid , 2-ethyl-3-OH-propionic , Urea , 4-Hydroxybutyric acid , 2-Hydroxyisocaproic acid , 3-Hydroxyvaleric acid , Acetoacetic acid , 2-Hydroxy-3-Methylvaleric acid , Benzoic acid , Acetoacetic acid-oxime , Octanoic acid , 2-Methyl-3-hydroxyvaleric acid , Glycerol , Phosphoric acid , Acetylglycine , Ethylmalonic acid , 2-Methyl-3-hydroxyvaleric acid , 2-Ketoisocaproic acid-oxime , Phenylacetic acid , Maleic acid , Succinic acid , Methylsuccinic acid , Glyceric acid , Fumaric acid , Uracil , Propionylglycine , Acetylglycine , Mevalonolactone , mevalonolactone-origin fragment , Isobutyrylglycine , 2-propyl-3-hydroxy-pentanoic acid , Mesaconic acid , Glutaric acid , 3-Methylglutaconic acid , 3-Methylglutaric acid , 2-Propyl-3-ketopentanoic acid , Propionylglycine , Isobutyrylglycine , 2-Deoxytetronic acid , Butyrylglycine , 3-Methylglutaconic acid(E) , Glutaconic acid , **succinylacetone** , decanoic , 2-Propyl-5-OH-pentanoic(VPA) , 3-methylglutaconic , isovalerylglycine , Butyrylglycine , Malic acid , Adipic acid , Phenyllactic acid , Isovalerylglycine , 2-Hexenedioic acid , 5-Oxoproline , Thiodiglycolic acid , 3-Methyladipic acid , 2-Propylglutaric acid , 7-Hydroxooctanoic acid , 5-Hydroxy-2-furoic acid , Tiglylglycine , 3-Methylcrotonoylglycine , Tiglylglycine , 3-Methylcrotonoylglycine , 3-Hydroxyglutaric acid , 2-Hydroxyglutaric acid , Pimelic acid , 3-Hydroxy-3-methylglutaric acid , 3-Hydroxyphenylacetic acid , 4-Hydroxybenzoic acid , 2-Ketoglutaric acid-oxime , 4-Hydroxyphenylacetic acid , 2-Ketoglutaric acid-oxime , Hexanoylglycine , Phenylpyruvic acid-oxime , N-Acetylaspartic acid , 2-Hydroxyadipic acid , Octenedioic acid , 3-Hydroxyadipic acid , Suberic acid , 3-Methylglutaconic acid , 2-Keto-adipic-OX , Aconitic acid , **Orotic acid** , Vanillic-2 (3-Methoxy-4-hydroxybenzoic acid) , **Homovanillic acid** , Azelaic acid , Hippuric acid , Isocitric acid , Citric acid , Hippuric acid , **Homogentisic acid** , Methylcitric acid , 3-(3-Hydroxyphenyl)-3-hydroxypropionic acid , Methylcitric acid , 3-Hydroxyoctenedioic acid , 3-Hydroxysebacic acid , **Vanilmandelic acid** , Sebacic acid , Decadienedioic acid , 4-Hydroxyphenyllactic acid , 4-Hydroxyphenylpyruvic acid-oxime , 2-Hydroxyhippuric acid , 3-Indoleacetic acid , Palmitic acid , 2-Hydroxysebacic acid , 3-Hydroxysebacic acid , 2-Hydroxyhippuric acid , Dodecanedioic acid , N-Acetyltyrosine , Uric acid , 3,6-Epoxydodecanedioic acid , Suberylglycine , 3-hydroxydodecanedioic acid , 3,6-Epoxytetradecanedioic acid .

GC/MS



Amino Acid Profile



HPLC



Homocysteine

Aspartic Acid,
 Glutamic Acid,
 Asparagine,
 Serine,
 Glutamine,
 Histidine,
 Glycine,
 Threonine,
 Citrulline,
 Arginine,
 Alanine,
 Tyrosine,
 Tryptophane,
 Methionine,
 Valine,
 Phenylalanine,
 Isoleucine,
 Leucine,
 Ornithine,
 Lysine

~~Homocysteine~~

Aminoacidopathies






| Disorders | Primary metabolite in MS/MS | Confirmatory tests / follow-up | Findings in confirmatory tests |
|--|--|--|---|
| Argininemia | ↑ Arginine | Plasma NH ₃ , PAA, enzyme assay | ↑ NH ₃ , ↑ arginine on PAA, ↓ hepatic arginase activity |
| Argininosuccinic aciduria (ASA) | ↑ Citrulline | Plasma NH ₃ , UAA, PAA, enzyme assay | ↑ NH ₃ , ↑ argininosuccinic acid on UAA and PAA, ↓ fibroblast/liver ASL activity |
| Citrullinemia Type 1 “Neonatal” citrullinemia | ↑ Citrulline | Plasma NH ₃ , PAA | ↑ NH ₃ , ↑ citrulline on PAA, ↓ fibroblast/liver ASS activity |
| Homocystinuria | ↑ Methionine | PAA, Hcy in P, UAA, UOA | ↑ Blood and urine homocyst(e)ine on PAA and UAA; ↑ urine methylmalonic acid on UOA in cobalamin C, D, F synthesis defects |
| Maple syrup urine disease (MSUD) | ↑ total “Leucine, isoleucine, alloisoleucine ↑ Valine | PAA, Urine DNPH, UOA | ↑ Leucine, isoleucine, alloisoleucine and valine on PAA; positive DNPH; ↑ branched chain α-keto and hydroxyl acids on UOA |
| Phenylketonuria | ↑ Phenylalanine ↑ phenylalanine tyrosine ratio | PAA, urine and/or blood or CSF neopterin and biopterin studies | ↑ Phenylalanine on PAA, ↑ phenylalanine/tyrosine ratio; abnormal urinary and/or blood or CSF pterins in BH ₄ synthesis defects |
| Tyrosinemia type 1 | ↑ Tyrosine | PAA, UOA | ↑ Tyrosine and methionine on PAA; ↑ succinylacetone and tyrosine metabolites on UOA |
| Tyrosinemia type 2 Oculocutaneous tyrosinemia | ↑ Tyrosine | PAA, UOA | ↑ Tyrosine on PAA; ↑ tyrosine metabolites without increased succinylacetone on UOA |

Samples for measurement of amino acids



- **Whole blood spotted on filter paper:** screens newborns for:
 - Many amino acidopathies
 - Urea cycle defects
- **Plasma:** identify patients with a suspected disorder of:
 - Amino acid metabolism
 - Monitoring treatment
- **Urine:** screen for:
 - Disorders of amino acid transport (cystinuria, lysinuric protein intolerance, or hartnup disease)
 - Generalized renal tubular dysfunction.
- **CSF** (usually in addition to plasma amino acids): evaluation of patients with:
 - Neurometabolic disorders (such as glycine encephalopathy)
 - Disorders of serine metabolism

Specimen Collection

The timing of the specimen collection is important in the detection of metabolic disorders.

- Acutely ill patients  Blood and urine specimens on admission
- Diagnosis of most amino acid disorders  **Overnight fast or at least 3 h after meal**
- Young infants  Immediately before the next scheduled feeding (**at least 2–3 h after the last feeding**)
- Hyperammonemia screening  Postprandial samples
- TPN patient  Intravenous hyperalimentation should be discontinued for at least 2–3 h prior to specimen collection

Hemolyzed samples

- The concentration of the majority of the physiological amino acids is the same in red blood cells and in plasma, with exception of **taurine, glutamate, aspartate**, and **argininosuccinate**
- The enzyme **arginase** converts arginine into ornithine and urea and is expressed in red blood cells. Hemolysis will release arginase in the plasma causing hydrolysis of arginine.
- Therefore, in hemolyzed samples:
 -  **Arginine**
 -  **Orn, Taurine, Glu, Asp, Argininosuccinate**

Handling and storage of samples

- Whole blood collected for amino acids analysis should be spun down as soon as possible.
- Plasma should be kept frozen during transport and until analysis is performed.
- Refrigerated conditions may be acceptable for a **short period** of time.
- Improper handling of specimens can result in artifactual changes in the amino acid contents.

Table 1. Collection, handling, and storage artifacts

| Factor/condition | Source | Amino acid(s) affected | Value |
|--------------------------------|--------|--------------------------------------|-------|
| Contamination, bacterial | U | Ala, Gly, Pro | ↑ H |
| Contamination, bacterial | U | Trp, aromatic amino acids, Ser | ↓ L |
| Contamination, fecal | U | Pro, Glu, Leu, Ile, Val, OH-pro-line | ↑ H |
| Contamination, protein | U | Cys | ↓ L |
| Contamination, RBC | U | Orn | ↑ H |
| Contamination, unwashed skin | B | Most amino acids | ↑ H |
| Contamination, WBC | U | Tau | ↑ H |
| Contamination, WBC | B | Asp, Glu, Tau | ↑ H |
| Hemolysis | B | Asp, Glu, Gly, Orn | ↑ H |
| Hemolysis | B | Arg, Gln | ↓ L |
| Serum vs. plasma | B | Serum Tau > plasma Tau | |
| Storage | U | Glu, Asp, GABA | ↑ H |
| Storage | U | Gln, Asn, phosphoethanolamine | ↓ L |
| Storage | B | Gln, Cys, homocystine | ↓ L |
| Storage | B | Glu | ↑ H |
| Tube artifact, thrombin | B | Gly | ↑ H |
| Tube artifact, EDTA | B | Ninhydrin positive artifact | |
| Tube artifact, metarsulfite | B | S-sulfocysteine | ↑ H |
| Unspun blood left at rm. temp. | B | Orn, total homocystine | ↑ H |
| Unspun blood left at rm. temp. | B | Arg, Cys, homocystine | ↓ L |

Table 2. Nutritional status and amino acid values

| Factor/condition | Source | Amino acid(s) affected | Value |
|---|--------|--|-------|
| Diet, canned formula or milk | U | Homocitrulline | ↑ H |
| Diet, gelatin | U | Gly | ↑ H |
| Diet, high protein (infants) | B | Met, Tyr | ↑ H |
| Diet, shellfish | U | Taurine | ↑ H |
| Diet, white meat from fowl | U | Anserine, 1-methylhistidine, carnosine | ↑ H |
| Folate deficiency | B | Total Homocyst(e)ine | ↑ H |
| Kwashiorkor | B | Pro, Ser, Gly, Phe | ↑ H |
| Kwashiorkor | B | Leu, Ile, Val, Trp, Met, Thr, Arg | ↓ L |
| Obesity | B | Branched chain amino acids, Phe, Tyr | ↑ H |
| Obesity | B | Gly | ↓ L |
| Starvation, 1–2 days (with or without vomiting) | B | Branched chain amino acids, Gly | ↑ H |
| Starvation, 1–2 days (with or without vomiting) | B | Alanine | ↓ L |
| Vitamin B12 deficiency | B | Total homocyst(e)ine | ↑ H |
| Vitamin B6 deficiency | U | Cystathionine | ↑ H |

Table 3. Effects of illness/disease on amino acid values

| Factor/condition | Source | Amino acid(s) affected | Value |
|--|--------|--|-------|
| Burn >20% of surface area (0–7 days after injury) | B | Phe | ↑ H |
| Burn >20% of surface area (0–7 days after injury) | U | Ala, Gly, Thr, Ser, Glu, Gln, Orn, Pro | ↓ L |
| Diabetes | B | Leu, Ile, Val | ↑ H |
| Hepatic disease | B | Tyr, Phe, Met, Orn, GABA | ↑ H |
| Hepatic disease | B | Branched chain amino acids | ↓ L |
| Hepatoblastoma | U | Cystathionine | ↑ H |
| Hyperinsulinism | B | Leu, Ile, Val | ↓ L |
| Hypoparathyroidism, primary | U | All amino acids | ↑ H |
| Infection | B | All amino acids | ↓ L |
| Infection | B | Phe/Tyr ratio | ↑ H |
| Infection | U | All amino acids | ↑ H |
| Ketosis | B | Leu, Ile, Val | ↑ H |
| Ketotic hypoglycemia | B | Ala | ↓ L |
| Leukemia, acute | U | Advanced disease: all amino acids | ↑ H |
| Leukemia, acute | U | On therapy: gly, asp, thr, ser | ↑ H |
| Neuroblastoma | U | Cystathionine | ↑ H |
| Renal failure | U | Phe, Val | ↓ L |
| Renal failure | U | His | ↑ H |
| Renal failure | B | Phe, Cit, Cys, Gln, homocyst(e)ine | ↑ H |
| Renal failure | B | Leu, Val, Ile, Glu, Ser | ↓ L |
| Respiratory distress on oxygen | B | Cystine | ↓ L |
| Rickets | U | Gly | ↑ H |

P plasma, *U* urine, *CSF* cerebrospinal fluid, *H* high, *L* low

Table 4. Effect of medications on amino acid values

| Factor/condition | Source | Amino acid(s) affected | Value |
|--|--------|--|-------|
| Arginine infusion | B | Arg | ↑ H |
| Arginine infusion | U | Arg, Lys, Orn, Cys | ↑ H |
| Bile acid sequestrants (colestipol, niacin) | B | Homocyst(e)ine | ↑ H |
| Cyclosporin A | B | Total homocysteine | ↑ H |
| 2-Deoxycoformycin | B | Homocyst(e)ine | ↓ L |
| Lysine aspirin | U | Lys | ↑ H |
| Methotrexate therapy | B | Homocyst(e)ine | ↑ H |
| Methotrexate therapy | B | Phe/Tyr ratio | ↑ H |
| Nitrous oxide anesthesia | B | Homocyst(e)ine | ↑ H |
| Oral contraceptives | B | Pro, Gly, Ala, Val, Leu, Tyr | ↓ L |
| D-Phenylalanine | U | Phe | ↑ H |
| Tamoxifen | B | Homocyst(e)ine | ↓ L |
| Tetracycline, renal toxicity | U | All amino acids | ↑ H |
| Valproate | B,U | Gly | ↑ H |
| Vigabatrin/ vinyl-GABA | U | β -alanine, β -aminoisobutyrate, GABA | ↑ H |
| Vigabatrin/ vinyl-GABA | CSF | GABA, β -alanine | ↑ H |
| Vigabatrin/ vinyl-GABA | B,U | 2-Aminoadipic acid | ↑ H |

P plasma, *U* urine, *CSF* cerebrospinal fluid, *H* high, *L* low

Urine sample

- Urine is not the fluid of choice in the diagnostic investigation of an aminoacidopathy (phenylketonuria, maple syrup urine disease, homocystinuria, etc.) as **plasma is a better sample type**.
- Urine amino acids analysis is the diagnostic test for **disorders of amino acid transport** (cystinuria, lysinuric protein intolerance, Hartnup) or in **prolidase deficiency**.
- Although a **random specimen** is usually sufficient for diagnostic purposes, a timed urine collection may be required for reabsorption studies in conjunction with a plasma sample collected at mid-point.
- The interpretation of urine amino acids relies on **patterns of amino acids** more than on absolute values.

Interpretation of Amino Acids

Results and Reference Values

Circadian rhythm

- Circadian rhythm is a physiological basis for higher amino acid concentrations, up to **10–15%**, in the blood in the **afternoon**.
- A mild generalized **increase** in urine amino acids is a relatively common finding in hospitalized children.
- **Vomiting and poor oral intake for 1–2 days** may cause mild elevations (two- to threefold) of the **plasma branched-chain amino acids**.

In a patient with MSUD and metabolic decompensation, the pattern of branched-chain amino acids will show a disproportionately **high leucine** compared to **isoleucine and valine** and a **markedly reduced alanine** in addition to the presence of **alloisoleucine**.

Interpretation of Amino Acids Results and Reference Values

Secondary amino acid changes

- Secondary amino acid changes can be a clue to other types of metabolic disorders such as:
 - Galactosemia
 - Organic acidemias
 - Disorders of pyruvate metabolism
- Gross elevations of many amino acids, particularly **glutamine** and **alanine** in blood, have been reported in moribund children.
- Elevations of the **branched-chain amino acids, citrulline, and arginine** can be secondary to **hypoxia** and **liver failure**.

Table 5. Pathologic conditions associated with abnormal amino acids concentrations

| Amino acid | Source | Disorder(s) | Value |
|-------------------------|-------------|---|-------|
| All amino acids | U | Classic galactosemia, Renal Fanconi syndrome, Lowe syndrome | ↑ H |
| All amino acids | U | Tyrosinemia type I, hereditary fructose intolerance | ↑ H |
| All amino acids | U | Vitamin D-dependent rickets, mitochondrial disorders | ↑ H |
| Neutral amino acids | U | Hartnup disorder | ↑ H |
| Alanine | P | Lactic acidosis, disorders of pyruvate metabolism, mitochondrial disorders, hyperammonemic syndromes, glucagon receptor defect | ↑ H |
| Alanine | P | Maple syrup urine disease | ↓ L |
| β-Alanine | P/U | β-Alaninemia | ↑ H |
| β-Alanine | CSF | GABA-transaminase deficiency | ↑ H |
| β-Alanine | U | Pyrimidine disorders, methylmalonate semialdehyde dehydrogenase deficiency | ↑ H |
| Allo-isoleucine | P/U/ CSF | Maple syrup urine disease, E ₃ deficiency | ↑ H |
| α-Amino adipic | U | α-Amino adipic/α-Keto adipic aciduria | ↑ H |
| β-Amino isobutyric acid | U | β-Alaninemia, β-Amino isobutyric acid aminotransferase deficiency (benign) | ↑ H |
| δ-Amino levulinic acid | U | Tyrosinemia type I, porphyria | ↑ H |
| Arginine | U | Cystinuria, dibasic aminoaciduria, lysinuric protein intolerance | ↑ H |
| Arginine | P | Arginase deficiency, glucagon receptor defect | ↑ H |
| Arginine | P | HHH syndrome, ornithine aminotransferase deficiency, urea cycle defects (except arginase deficiency) | ↓ L |
| Argininosuccinate | P/U/ CSF | Argininosuccinate lyase deficiency | ↑ H |
| Asparagine | P/CSF | Asparagine synthase deficiency | ↓ L |
| Aspartic acid | U | Dicarboxylic aminoaciduria | ↑ H |
| Aspartic acid | U | Pyruvate carboxylase deficiency type B | ↓ L |
| Aspartylglucosamine | P/U | Aspartylglucosamidase deficiency | ↑ H |
| Carnosine | U | Carnosinemia | ↑ H |
| Citrulline | P | Citrullinemia type I (argininosuccinate synthase deficiency), Citrullinemia type II (citrin deficiency), argininosuccinate lyase deficiency, pyruvate carboxylase deficiency type B | ↑ H |

Table 5. (continued)

| Amino acid | Source | Disorder(s) | Value |
|---------------------------------|-------------|---|-------|
| Citrulline | P | Δ -pyrroline-5-carboxylate synthase deficiency, lysinuric protein intolerance, NAGS, CPS, OTC deficiencies, mitochondrial disorders | ↓ L |
| Cystathionine | P/U | Cystathionase deficiency | ↑ H |
| Cystine | U | Cystinuria, hyperlysinemia, hyperornithinemia | ↑ H |
| Cystine | P | Molybdenum cofactor deficiency, sulfite oxidase deficiency | ↓ L |
| Formiminoglutamic acid (FIGLU) | U | Formiminoglutamic aciduria | ↑ H |
| GABA | P/U | β -Alaninemia | ↑ H |
| GABA | P/U/ CSF | GABA transaminase deficiency | ↑ H |
| Glutamic acid | U | Dicarboxylic aminoaciduria | ↑ H |
| Glutamic acid | P | Glutamic acidemia, glutamine synthase deficiency | ↑ H |
| Glutamine | P/U/ CSF | Urea cycle defects | ↑ H |
| Glutamine | P | Glutaminase deficiency (normal ammonia) | ↑ H |
| Glutamine | P | Glutamine synthase deficiency, propionic acidemia, methylmalonic acidemia, maple syrup urine disease, pyruvate carboxylase deficiency | ↓ L |
| Glycine | P/U/ CSF | Glycine encephalopathy, glycine transporter deficiency, propionic acidemia, methylmalonic acidemia, D-Glyceric aciduria | ↑ H |
| Glycine | U | Familial renal iminoglycinuria, hyperprolinemia type I and II | ↑ H |
| Glycine | P/CSF | Serine deficiency disorders | ↓ L |
| Glycylproline | U | Prolidase deficiency | ↑ H |
| Hawkinsin | U | Hawkinsinuria | ↑ H |
| Histidine | P/U | Histidinemia | ↑ H |
| Homoarginine | P/U | Hyperlysinemia | ↑ H |
| Homocarnosine | CSF | Homocarnosinosis | ↑ H |
| Homocitrulline | P/U | HHH syndrome, saccharopinuria | ↑ H |
| Homocyst(e)ine | P/U | Cystathionine- β -synthase deficiency, cobalamin disorders, folate disorders, methionine synthase (MS) and MS reductase deficiency | ↑ H |
| Homocyst(e)ine | P | Methionine adenosyltransferase deficiency, S-Adenosylhomocysteine hydrolase deficiency, glycine-N-methyltransferase deficiency, adenosine kinase deficiency | ↑ H |
| Homocysteine-cysteine disulfide | P | Cystathionine- β -synthase deficiency | ↑ H |
| Total Homocysteine | P | Molybdenum cofactor deficiency, sulfite oxidase deficiency | ↓ L |
| Hydroxylysine | U | Hydroxylysineuria | ↑ H |
| Hydroxyproline | U | Familial renal iminoglycinuria, hyperprolinemia type I and II | ↑ H |
| Hydroxyproline | P/U | Hydroxyprolinemia | ↑ H |
| Imidodipeptides | U | Prolidase deficiency | ↑ H |
| Isoleucine | P/U | Maple syrup urine disease, E3 deficiency | ↑ H |
| Leucine | P/U | Maple syrup urine disease, E3 deficiency | ↑ H |
| Lysine | U | Cystinuria, lysinuric protein intolerance, dibasic aminoaciduria | ↑ H |
| Lysine | P/U | Hyperlysinemia, saccharopinuria | ↑ H |
| Lysine | P | HHH syndrome, ornithine aminotransferase deficiency, lysinuric protein intolerance | ↓ L |
| Lysine | P | Urea cycle defects, pyruvate carboxylase deficiency type B | ↑ H |
| Methionine | P/CSF | Homocysteine remethylation disorders | ↓ L |
| Methionine | P/U | Cystathionine- β -synthase deficiency, hypermethioninemias | ↑ H |
| Methionine sulfoxide | P | Cystathionine- β -synthase deficiency, hypermethioninemias | ↑ H |
| Ornithine | U | Cystinuria, dibasic aminoaciduria, hyperlysinemia, lysinuric protein intolerance | ↑ H |
| Ornithine | P | HHH syndrome, ornithine aminotransferase deficiency | ↑ H |
| Ornithine | P | Δ -pyrroline-5-carboxylate synthase deficiency | ↓ L |
| Phenylalanine | P/U | Phenylketonuria, hyperphenylalaninemias, pterin disorders | ↑ H |
| Phenylalanine | P | Tyrosinemia type I | ↑ H |
| Phosphoethanolamine | U | Hypophosphatasia | ↑ H |
| Pipecolic acid | P | Hyperlysinemia, antiquitin deficiency (pyridoxine responsive seizures) | ↑ H |
| Pipecolic acid | U | Hyperprolinemia type II | ↑ H |
| Pipecolic acid | P/U | Peroxisomal disorders | ↑ H |
| Proline | P | Δ -pyrroline-5-carboxylate synthase deficiency | ↓ L |

Table 5. (continued)

| Amino acid | Source | Disorder(s) | Value |
|-----------------|--------|--|-------|
| Proline | U | Familial renal iminoglycinuria | ↑ H |
| Proline | P/U | Hyperprolinemia type I and II, lactic acidosis, multiple acyl-CoA dehydrogenase deficiency | ↑ H |
| Saccharopine | P/U | Saccharopinuria | ↑ H |
| Sarcosine | P/U | Sarcosinemia, mitochondrial disorders, glutaric acidemia type II, Betaine therapy | ↑ H |
| Serine | P/CSF | Serine deficiency disorders | ↓ L |
| S-Sulfocysteine | P/U | Molybdenum cofactor deficiency, sulfite oxidase deficiency | ↑ H |
| Taurine | U | Molybdenum cofactor deficiency, sulfite oxidase deficiency, β-Alaninemia | ↑ H |
| Threonine | P/CSF | Pyridoxal phosphate-dependent seizures, citrullinemia type II (citrin deficiency) | ↑ H |
| Tryptophan | U | Tryptophanuria | ↑ H |
| Tyrosine | P/U | Tyrosinemia type I, II, III, transient tyrosinemia of the newborn | ↑ H |
| Tyrosine | P | Phenylketonuria, pterin disorders | ↓ L |
| Valine | P/U | Maple syrup urine disease, E3 deficiency, branched chain amino transferase 2 deficiency | ↑ H |

P plasma, *U* urine, *CSF* cerebrospinal fluid, *H* high, *L* low

Table V: Maternal conditions affecting the newborn screening results

| Maternal conditions | NBS analyte affected | Results in | Additional information/ duration of interference |
|--|---|---|--|
| Hyperthyroidism treated with Propylthiouracil (PTU) | Low thyroxine (T4), high TSH | Transient hypothyroidism | Until drug clears, typically 7-14 days |
| ¹³¹ I (radioactive iodine) treatment during pregnancy: Before 8 weeks' gestation. | none | Euthyroid (but may cause birth defects) | Will cause maternal hypothyroidism (potential effect on fetal brain development if not treated in first trimester) |
| ¹³¹ I (radioactive iodine) treatment during pregnancy: After 8 weeks' gestation (when fetal thyroid matures and traps iodine) | Low T4, high TSH | Permanent hypothyroidism | Lifelong |
| Steroids: prednisone, betamethasone/dexamethasone | Low or normal 17-OHP | Suppresses fetal adrenal function and causes false-negative results for CAH | Unknown - depends on class of steroid and dose; estimate 1-2 weeks |
| CAH | Elevated 17-OHP | False-positive result | Unknown-estimate 3-7 days |
| PKU or moderate hyperphenylalaninemia uncontrolled by diet or medications | Elevated phenylalanine; although ratio of phenylalanine - to - tyrosine (Phe/Tyr) should be normal; false-positive result | Transient hyperphenylalaninemia | 12-24 hours unless infant has PKU |
| 3-MCC deficiency | Elevated C50H | False-positive result | Unknown |
| Fatty liver of pregnancy or HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) | May have elevated even chain acylcarnitines | False-positive result | Unknown |
| Carnitine deficiency | May have low carnitine levels | False-positive result | Unknown |
| Vitamin B12 deficiency | Elevated propionylcarnitine (C3) | False-positive result | A number of days depending on nutrition provided |

Table VI: Treatments used in special care baby unit and effects on newborn screening results

| Treatment | Effect on newborn screening results | Duration of effect |
|--|--|--|
| Parenteral Nutrition (PN) | Elevation of multiple amino acids | 4–24 hours after PN discontinued |
| Carnitine supplementation | Elevations of acylcarnitines; can mask carnitine transport disorders | For duration of supplementation and weeks later |
| Red cell transfusion and Extra Corporeal Life Support (ECLS) (pre- and postnatal transfusions) | Can mask the absence of enzymes and proteins intrinsic to the red blood cell (RBC), thereby negating results for hemoglobinopathies and galactosemia (when testing is for galactose 1 phosphate uridyl transferase (GALT) enzyme activity) | 120 days after last transfusion ECLS invalidates all NBS results for analyte-specific periods of time |
| Dopamine | False-negative testing for CH, because levels of TSH are suppressed | Until drug therapy is stopped |
| Steroids | Suppressed TSH and T4; possible false-negative result for CH. May suppress 17-OHP resulting in false-negative testing for CAH | Unknown - depends on class of steroid and dose; estimate 1–2 weeks |
| Iodine exposure with povidone/iodine preps | Transient hypothyroidism; low T4, elevated TSH | Once exposure to topical iodine discontinued, resolution may take 2–6 weeks (depending on dose absorbed and other factors) |
| Pivalic acid antibiotic therapy | May cause elevated isovaleryl 2-methylbutyryl carnitine | Unknown |

Table VII: Conditions of the infant affecting newborn screening tests

| Condition of the infant | Effect on newborn screening | Duration of effect |
|--|---|--------------------------|
| Immature hypothalamic-pituitary thyroid axis | Low T4, normal TSH, infants with congenital hypothyroidism (CH) can be missed | Up to 6 weeks of age |
| Hypothyroxinemia of preterm birth | Transient hypothyroidism, low T4; normal TSH followed by elevated TSH | Up to 6 weeks of age |
| Liver enzyme immaturity | Transient elevations of tyrosine, methionine, and galactose, occasionally other amino acids | A few weeks |
| Iodine deficiency | Transient hypothyroidism low T4, elevated TSH | Until supplemented |
| Acute illness | Transient hypothyroidism; low T4, elevated TSH, elevated immunoreactive trypsinogen (IRT) | Until recovered |
| Hypoxia | Elevated IRT | Until recovered |
| Liver disease | Elevated tyrosine, methionine, galactose Depression of biotinidase enzyme | Until recovered |
| Renal immaturity | Elevated 17-OHP, amino acids | Until recovered |
| Preterm | Lower biotinidase levels inversely related to gestational age | 40 weeks gestational age |

تفسیر آزمایشات متابولیک






Figure 84-1. Clinical approach to a newborn infant with a suspected metabolic disorder. This schema is a guide to the elucidation of some of the metabolic disorders in newborn infants. Although some exceptions to this schema exist, it is appropriate for most cases.

Amino acid disorders



- Hyperammonemia:** Neos: > 50...> 100; Kids/Adults: >100...>150
- Level of hyperammonemia: 1) urea cycle defect 2) organic acidemia 3) amino acidopathy
 - Central hyperventilation → respiratory alkalosis
 - Why is it bad? Cerebral edema → herniation



1) **UCD**: elevation of ammonia without metabolic acidosis (sometimes respiratory alkalosis)

Normal Level of ammonia:

- Fullterm < 100 $\mu\text{mol/L}$ (< 1.7 $\mu\text{g/ml}$)
- Preterm < 150 $\mu\text{mol/L}$ (< 2.6 $\mu\text{g/ml}$)
- Children < 35 $\mu\text{mol/L}$ (< 0.6 $\mu\text{g/ml}$)

Pathologic Level of ammonia:

Neonate: > 150 $\mu\text{mol/L}$ (> 2.6 $\mu\text{g/ml}$)

Ch.-Ad: > 100 $\mu\text{mol/L}$ (> 1.7 $\mu\text{g/ml}$)

MS/MS: Increased level of

- ❖ Citruline
- ❖ Glutamic acid
- ❖ Aspartic acid
- ❖ Alanine

Urine GCMS: Increased level of:

- ❖ orotic acid
- ❖ uracil

Orotic acid

- **Indic.:** Suspected heterozygous OTC deficiency, urea cycle defects carbamyl phosphate disorder, disorders of pyrimidine metabolism, mitochondrial disorders, allopurinol test
- **Method:** HPLC, MS-MS, capillary electrophoresis
- unexplained elevations also in other disorders, e.g. **Rett** syndrome, **Lesch-Nyhan** syndrome,
- “benign orotic aciduria

Elevation of other amino acids

- **Citrulline:** DD: citrullinaemia: ↑ Cit;
argininosuccinic aciduria: ↑ Cit, ↑ Asa,
Renal disease
- Confirmation: AA plasma and urine
- **Arginine:** Argininaemia; low sensitivity, Arg frequently normal in newborns
- Confirmation: AA plasma and urine
- **Glycine:** Non-ketotic hyperglycinaemia
- Confirmation: AA plasma (if symptomatic: plasma + CSF)

Follow-up testing for elevated citrulline

- *Possible diagnosis: citrullinemia (ASD);*
- *argininosuccinic aciduria (ASLD)* Plasma amino acids - elevated Cit, also Asa in ASLyase
- Urine amino acids (grossly elevated arginino-succinic acid (Asa) is diagnostic of ASL def)
- Urine organic acids - orotic acid may be elevated
- Confirmation:
- Argininosuccinate **synthetase** (ASS) activity in liver or cultured fibroblasts
- Argininosuccinate lyase (ASL) deficiency is confidently diagnosed from Asa levels

(فرم جواب به پیوسته علت آنالیزها در برنامه کشوری غربالگری نوزادان)

Report Form for Derivatized Sample Analysis by MS-MS Assay



| | | |
|--|---------------------------------|---|
| نام نوزاد : امیررضا میرزایی | نام مادر: سمیرا | نام آزمایش: نام از مایتن: |
| تاریخ تولد ۱۴۰۰/۰۷/۰۳ | تاریخ نمونه گیری: ۱۴۰۰/۰۷/۲۴ | تاریخ : ۱۴۰۰/۰۷/۲۹ |
| جنسیت نوزاد : مرد | تاریخ دریافت نمونه : ۱۴۰۰/۰۷/۲۷ | روش آزمایش: تاندم مس اسپکترومتری مشق سازی sciex 3200 |
| مرکز ارسال کننده : شهید احمدی - تهران جنوب | تاریخ پذیرش : ۱۴۰۰/۰۷/۲۷ | کد پذیرش ۲۴ رقمی کشوری نمونه ۰۱۱۰۰۰۷۲۷۰۰۰۰۲۱۰۲۱۰۴۲۲۲۱ |
| شماره کافد گاتری از مرکز بهداشتی : ۷/۱۸-۱۰۵۰ | تاریخ گزارش : ۱۴۰۰/۰۷/۲۹ | |

| Analyte Abbreviation | Analyte Full name | Result (µM) | reference interval | pathologic border | Description |
|----------------------|--|-------------|--------------------|-------------------|-------------|
| Ala | Alanine | 189.00 | <362 | >514 | Normal |
| Asp | Aspartic Acid | 30.50 | <84 | >95 | Normal |
| Glu | Glutamic Acid | 203.00 | <427/00 | >461 | Normal |
| Arg | Arginine | 13.50 | 4/00-34 | <4 , >42 | Normal |
| Cit | Citrulline | 48.40 | 5.0-21.0 | <4 , >30 | * |
| Gly | Glycine | 214.00 | <417 | >486 | Normal |
| Leu+Ile | Leucine+Isoleucine | 107.00 | <170 | >191 | Normal |
| Met | Methionine | 20.60 | 9.0-32 | <9 , >36 | Normal |
| Orn | Ornithine | 49.60 | <133 | >148 | Normal |
| Phe | Phenylalanine | 34.30 | <69 | >112 | Normal |
| Pro | Proline | 89.80 | <292 | >314 | Normal |
| Tyr | Tyrosine | 43.90 | <264 | >303 | Normal |
| Val | Valine | 73.20 | <156 | >166 | Normal |
| C0 | Free Carnitine | 14.90 | 8/0-40 | <6/5 , >45 | Normal |
| C2 | Acetylcarnitine | 6.94 | 7-38 | <5 , >40 | * |
| C3 | Propionylcarnitine | 0.39 | 0.3-4/6 | <0.3 , >5/0 | Normal |
| C3DC & C8OH | Malonylcarnitine & 8-Hydroxyoctanoylcarnitine | 0.02 | <0/05 | >0/15 | Normal |
| C4 | Butyrylcarnitine | 0.14 | <0.55 | >0/75 | Normal |
| C4OH | Hydroxybutyrylcarnitine | 0.03 | <0.3 | >0.5 | Normal |
| C4DC | Methylmalonylcarnitine | 0.15 | <0/25 | >0.34 | Normal |
| C5 | Isovalerylcarnitine | 0.13 | <0.36 | >0.45 | Normal |
| C5DC & C10OH | Glutarylcarnitine & 3-Hydroxydecanoylcarnitine | 0.03 | <0/15 | >0.16 | Normal |
| C5:1 | Tiglylcarnitine | 0.01 | <0.03 | >0.09 | Normal |
| C5OH | Hydroxyisovalerylcarnitine | 0.10 | <0/27 | >0.47 | Normal |
| C6 | Hexanoylcarnitine | 0.01 | <0.09 | >0.12 | Normal |
| C6DC | Adipoylcarnitine | 0.01 | <0.05 | >0.06 | Normal |
| C8 | Octanoylcarnitine | 0.02 | <0.08 | >0.28 | Normal |



۱۴۰۲/۰۶/۰۶ ۱۴:۴۵

تاریخ چاپ:

آزاد

نوع بیمه:

دکتر طالع - علی

پزشک معالج:

۵۳۷۱۱۴۱

کد پذیرش:

HPLC

| <u>Test</u> | <u>Result</u> | <u>Unit</u> | <u>Reference Value</u> |
|---------------------|---------------|---------------|------------------------|
| Aspartic Acid | 7.8 | uMol/L | 0-20 |
| Glutamic Acid | 106.7 | uMol/L | 10-120 |
| Asparagine | 28.0 | uMol/L | 24-60 |
| Serine | 120.0 | uMol/L | 60-200 |
| Glutamine | 286.2 | uMol/L | 396-746 |
| Histidine | 58.7 | uMol/L | 50-130 |
| Glycine | 233.6 | uMol/L | 140-490 |
| Threonine | 89.9 | uMol/L | 40-240 |
| Citrulline | 78.5 | uMol/L | 8-47 |
| Arginine | 29.0 | uMol/L | 40-160 |
| Taurine | 52.1 | uMol/L | 19-216 |
| Alanine | 134.5 | uMol/L | 240-600 |
| Tyrosine | 90.6 | uMol/L | 30-120 |
| α-Aminobutyric Acid | 4.1 | uMol/L | 6-38 |
| Tryptophane | 33.4 | uMol/L | 15-73 |
| Methionine | 17.7 | uMol/L | 6-49 |
| Valin | 90.1 | uMol/L | 140-350 |
| Phenylalanine | 58.7 | uMol/L | 30-80 |
| Isolucine | 22.3 | uMol/L | 30-130 |
| leucine | 51.8 | uMol/L | 60-230 |
| Ornitine | 50.3 | uMol/L | 20-135 |
| Lysine | 56.5 | uMol/L | 80-250 |

Comment: پلاسما اینکتر:

* Rechecked

Dr. Signature:



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-LA-RS-00-091482

date:00/09/18

Name of Lab Center: Iran Metabolic Center
Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

| | | |
|----------------------------------|-------------------------|---------------------------------------|
| Patient's name: Amirreza Mirzaei | Lab number:9337 | Patient's ID:012000917000213014041482 |
| Sample type: urine | Gender: male | age:2m, 13d |
| Physician/referred by: CMC | Reception Date:00/09/17 | Reporting date: 00/09/18 |

Result:

| Abnormal Compound | Cut off | measure |
|-------------------|---------|---------|
| Ethylmalonic acid | 7.45% | 8.24% |
| Octanoic acid | 0.59% | 0.64% |

Comment:

The urine organic acid analysis shows increased level of Ethylmalonic acid and Octanoic acid, that may be due to fasting. MCT oil consumption or carnitine deficiency.

Differential diagnosis

| <i>Plasma citrulline</i> | <i>Other features</i> | <i>Diagnosis</i> |
|--------------------------|---|--|
| Low (usually) | ↑↑ Orotic acid | Ornithine transcarbamylase deficiency |
| | Specific acylcarnitines and organic acids | Organic aciduria, e.g. propionic or methylmalonic aciduria |
| | ↓-n Orotic acid | Carbamylphosphate synthase deficiency N-acetylglutamate synthase deficiency Ornithine aminotransferase deficiency (newborns) |
| >30 μM | ↑ Orotic acid | Lysinuric protein intolerance |
| >50 μM | ↓-n Orotic acid, ↑ lactate | Pyruvate carboxylase deficiency (neonatal) |
| 100–300 μM | ↑ Argininosuccinate | Argininosuccinic acidaemia |
| >1,000 μM | ↑ Orotic acid | Citrullinaemia |



فرم جوابدهی آزمایشگاه شناسایی و تشخیص بیماری‌های
متابولیک ارثی
(فرم جواب به پیوست سلامت خانواده در برنامه کشوری غربالگری نوزادان)

HD-IMC-LA-Rs-01-120646

تاریخ : 1401/12/10



نام آزمایش:
آنالیز نمونه خون خشک شده روی کاغذ از نظر
عملکرد متابولیک ارثی
روش آزمایش: تاندوم مس اسپکترومتری
عبر مشتق سازی

نام مادر : سمیرا

نام نوزاد : سیده ملکا رضایی

تاریخ نمونه گیری : 1401/11/30

تاریخ تولد : 1401/11/24

تاریخ دریافت نمونه : 1401/12/08

جنسیت نوزاد : زن

قد پذیرش 24 رقی کشور نمونه

تاریخ پذیرش : 1401/12/08

مرکز ارسال کننده : ثلاث - تهران جنوب

01101120800006021020646

تاریخ گزارش : 1401/12/10

شماره کاغذ کتوری از مرکز بهداشتی : 7

| Analyte Abbreviation | Analyte Full name | Result (µM) | reference interval | pathologic border | Description |
|----------------------|---|-------------|--------------------|-------------------|-------------|
| Ala | Alanine | 237.71 | 83-332 | >467 | Normal |
| Arg | Arginine | 16.53 | 3.39-51.31 | <2.80 , >62.07 | Normal |
| Cit | Citrulline | 68.66 | 4.4-27 | <3 , >50 | * |
| Glu | Glutamic Acid | 331.88 | 172.2-645.1 | >723 | Normal |
| Gly | Glycine | 172.90 | 69.3-308.5 | >336.6 | Normal |
| Leu+Ile | Leucine+Isoleucine | 113.25 | 48-201 | >215 | Normal |
| Met | Methionine | 22.08 | 7.06-27.84 | <6.37 , >34.25 | Normal |
| Orn | Ornithine | 71.09 | 48.55-182 | >202 | Normal |
| Phe | Phenylalanine | 45.74 | 25.21-79.94 | >119 | Normal |
| Pro | Proline | 211.93 | 81-374 | >404 | Normal |
| Tyr | Tyrosine | 188.21 | 40.1-267.6 | >296.4 | Normal |
| Val | Valine | 104.64 | 42.3-148 | >159 | Normal |
| C0 | Free Carnitine | 16.191 | 7.14-43.34 | <5.6 , 48 | Normal |
| C2 | Acetylcarnitine | 7.551 | 5.92-40.68 | <3.95 , >45.29 | normal |
| C3 | Propionylcarnitine | 1.087 | 0.37-4.30 | <0.2 , >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.021 | <0.25 | >0.44 | Normal |
| C4 | Butyrylcarnitine | 0.152 | 0.085-0.7 | >0.97 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.125 | <0.31 | >1.14 | Normal |
| C5 | Isovalerylcarnitine | 0.127 | <0.53 | >0.63 | Normal |
| C5-1 | Tiglylcarnitine | - | <0.074 | >0.23 | |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.201 | <0.45 | >0.49 | Normal |
| C6 | Hexanoylcarnitine | 0.033 | <0.10 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.166 | <0.46 | >0.5 | Normal |
| C8 | Octanoylcarnitine | 0.027 | <0.10 | >0.38 | Normal |
| C8:1 | Octenoylcarnitine | 0.068 | <0.19 | >0.24 | Normal |
| C10 | Decanoylcarnitine | 0.035 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.063 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienyl carnitine | 0.018 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.034 | <0.146 | >0.26 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.019 | <0.09 | >0.15 | Normal |
| C14 | Tetradecanoylcarnitine | 0.101 | <0.36 | >0.58 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.023 | <0.13 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.009 | <0.025 | >0.042 | Normal |

END OF KESHAVARZ BLVD.-DR.GHARIB ST.

بیمارستان دکتر حسن اهری اسپهلی بوار ساورز خیابان د نمر فریب ۳-۹۸۱-۶۶۹۲

| | | | |
|------------------------------|---------------------------|-----------------|--------------------------------|
| شماره آزمایشگاه : L011216141 | نام : سیده ملکا رضانی حور | جنس : زن | تاریخ پذیرش : ۱۴۰۱/۱۲/۲۷ ۱۱:۱۹ |
| کد برگه : ۳۶۱۶۲۴۵ | نام پدر : سیداحمد | سن : ۱ ماه | تاریخ جواب : ۱۴۰۲/۰۱/۰۹ ۰۹:۴۳ |
| کد پذیرش : ۶۰۰۷۹۹۳ | پزشک معالج : ----- | نوع بیمه : آزاد | تاریخ چاپ : ۱۴۰۲/۰۶/۰۶ ۱۴:۴۴ |

HPLC(plasma)

| Test | Result | Unit | Reference Value |
|--------------------|--------|--------|-----------------|
| Aspartic Acid | 9.4 | uMol/L | 0-20 |
| Glutamic Acid | 308.8 | uMol/L | 10-120 |
| Asparagine | 49.4 | uMol/L | 24-60 |
| Serine | 177.4 | uMol/L | 60-200 |
| Glutamine | 614.2 | uMol/L | 396-746 |
| Histidine | 121.7 | uMol/L | 50-130 |
| Glycine | 279.3 | uMol/L | 140-490 |
| Threonine | 216.8 | uMol/L | 40-240 |
| Citrulline | 173.2 | uMol/L | 8-17 |
| Arginine | 213.6 | uMol/L | 40-160 |
| Taurine | 46.7 | uMol/L | 19-216 |
| Alanine | 298.9 | uMol/L | 240-600 |
| Tyrosine | 151.5 | uMol/L | 30-120 |
| a-Aminobutric Acid | 15.0 | uMol/L | 6-38 |
| Tryptophane | 39.9 | uMol/L | 15-73 |
| Methionine | 38.1 | uMol/L | 6-49 |
| Valin | 169.7 | uMol/L | 140-350 |
| Phenylalanine | 62.6 | uMol/L | 30-80 |
| Isolucine | 62.6 | uMol/L | 30-130 |
| leucine | 90.8 | uMol/L | 60-230 |
| Ornitine | 52.0 | uMol/L | 20-135 |
| Lysine | 123.1 | uMol/L | 80-250 |

* Rechecked

Dr Signature :

نام: سیده ملکا رضایی حور
 نام پزشک: دکتر علی طالع
 سن: 4 ماهه
 تاریخ پذیرش: 02/03/24
 شماره: 40824
 تاریخ جواب: 02/04/07

Amino Acids profile in plasma by LC MS/MS

| Amino Acid | Result (µM) | Normal Value | Description |
|---------------------------|-------------|--------------|-------------|
| Alanine | 228.1 | 139-474 | Normal |
| Allo-isoleucine | 0.3 | < 2 | Normal |
| Alpha-aminoadipic acid | 0.7 | <4 | Normal |
| Arginine | 35.5 | 19-136 | Normal |
| Argininosuccinic acid | 15.5 | < 0.2 | Abnormal |
| Asparagine | 51.6 | 25-91 | Normal |
| Aspartic acid | 6.8 | < 20 | Normal |
| Beta-aminoisobutyric acid | 2.7 | < 5 | Normal |
| Beta-alanine | 4.9 | <28 | Normal |
| Citrulline | 91.3 | 9-45 | Abnormal |
| Cystathionine | 0.0 | <1 | Normal |
| Cystine | 6.5 | 2-25 | Normal |
| Gamma-aminobutyric acid | 0.2 | <1.5 | Normal |
| Glutamic acid | 109.3 | 31-202 | Normal |
| Glutamine | 759.2 | 316-850 | Normal |
| Glycine | 195.8 | 111-426 | Normal |
| Glycylproline | 0.0 | <0.5 | Normal |
| Histidine | 46.8 | 10-116 | Normal |
| Homocitrulline | 0.1 | <1 | Normal |
| Homocystine | 0.0 | <0.2 | Normal |
| Hydroxylysine | 0.1 | <0.5 | Normal |
| Hydroxyproline | 35.8 | 8-61 | Normal |
| Isoleucine | 33.6 | 25-105 | Normal |
| Leucine | 53.8 | 48-195 | Normal |
| Lysine | 108.0 | 49-283 | Normal |
| Methionine | 19.8 | 11-44 | Normal |
| Ornithine | 47.9 | 20-130 | Normal |
| Phenylalanine | 45.5 | 28-102 | Normal |
| Proline | 159.8 | 85-303 | Normal |
| Serine | 126.5 | 69-271 | Normal |
| Sulfocysteine | 0.0 | <1 | Normal |
| Threonine | 137.2 | 47-237 | Normal |
| Tryptophan | 64.5 | 17-134 | Normal |
| Tyrosine | 76.8 | 26-115 | Normal |
| Valine | 96.0 | 83-312 | Normal |

Interpretation: This result is compatible with biochemical diagnosis of "Argininosuccinate Lyase Deficiency."

This test has been done with cooperation with Farzanegan Lab.

Follow-up testing for elevated arginine

- *Possible diagnosis: arginase deficiency*
- Plasma amino acids - marked elevation of Arg
- Urine amino acids - elevated Arg, Lys, Cys, Orn
- Urine organic acids - orotate
- Confirmation: Arginase activity (RBC)

Follow-up testing for elevated ornithine

- *Possible diagnosis: HHH syndrome; gyrate atrophy*
- Plasma amino acids - markedly elevated Orn
- • Urine amino acids - elevated Orn, homoCit
- • Urine organic acids - orotic acid
- • Confirmation:
 - elevated ammonia in addition to Orn and increased
 - excretion of homocitrulline (homoCit) are diagnostic of
 - HHH syndrome - a mitochondrial membrane
 - transporter defect (ORNT1)
 - • ornithine aminotransferase activity in lymphocytes
 - (gyrate atrophy)

تفسیر آزمایشات متابولیک




Figure 84-1. Clinical approach to a newborn infant with a suspected metabolic disorder. This schema is a guide to the elucidation of some of the metabolic disorders in newborn infants. Although some exceptions to this schema exist, it is appropriate for most cases.

- The most common abnormality in NBS for amino acids is elevated **tyrosine**; most cases are NOT tyrosinemia I, II or III (these are very rare)
- The most common urea cycle defect, **OTC deficiency**, is not currently detectable by MS/MS (possibility of low citrulline?)
- It is not clear that Tyr-I, NKH, HHH, Hyperprolinemia or Arginase deficiency are detectable in the neonate (< 5d of age)

Aminoacidopathies

2/A) PKU:

High blood level of phenylalanine (usually above than 10mg/dl) is diagnostic in:

- **HPLC** method
- **MS/MS** method (mass spectrometry/ mass spectrometry)

GCMS: Increased level of metabolites:

- Phenyl acetate
- Phenyl lactate
- Phenyl pyrovate

Phenylketonuria (PKU;)

- Metab.: ↑ Phe, ↓ Tyr, ↑ Phe/Tyr ratio
- Confirm.: AA plasma; exclude cofactor deficiency **pterines** in urine, DHPR activity in DBS; consider BH4 test
- **DD:** Prematurity, liver disease/hepatic failure, parenteral nutrition; ↑ Phe + ↑ Tyr: tyrosinaemia type 2 or 3, transient hypertyrosinaemia (premature neonates)
- Neonatal Presentation: None

Pre-analytical aspects PHE

- Potential for **false negatives** PHE

Missing sample spot in the plate well

Transfusions at least **72h**

Delays in transit

Physiological reasons

Potential for **false positives**

Contamination of the sample

Non-sample source contamination

Physiological reasons

2/B) Tyrosinemia: Blood level elevation of tyrosine:

- HPLC method ,MS/MS method (mass spectrometry/mass spectrometry)

❖ **GCMS:** Elevation of:

❖ Succinylacetone

❖ N-acetyltirosine

❖ 4 -HPPA

❖ 4 -HPLA

❖ 4 -HPAA

Follow-up testing for elevated tyrosine

Possible diagnosis: tyrosinemia type I, II or III

- Plasma amino acids - elevated Tyr
- Urine organic acids (elevated tyrosine metab; **succinylacetone** is diagnostic of **type I**)
- **TYR II or III - Elevated TYR with normal SUAC**
 - Clinical history (hepatorenal phenotype - type I; oculocutaneous phenotype - type II)
- **DD:** types 2 and 3, transient hypertyrosinaemia (mainly premature neonates)
 - *Note: transient tyrosinemia of the newborn is by far the most common cause of elevated Tyr*

| تاریخ پذیرش : 1401/01/28 | | مرکز ارسال کننده : اسماعیل آباد - تهران جنوب | | | |
|---|---|--|--------------------|--|-------------|
| کد پذیرش 24 رگمی کشوری نمونه 01101012800004021043457 | | تاریخ گزارش : 1401/01/31 | | شماره کاغذ گاتری از مرکز بهداشتی : 670 | |
| Analyte Abbreviation | Analyte Full name | Result (µM) | reference interval | pathologic border | Description |
| Ala | Alanine | 253.08 | <332 | >467 | Normal |
| Arg | Arginine | 11.42 | 3.39-51.31 | <2.80 , >62.07 | Normal |
| Cit | Citrulline | 11.54 | 5.2-27 | <3 , >50 | Normal |
| Glu | Glutamic Acid | 409.16 | <593 | >723 | Normal |
| Gly | Glycine | 146.37 | <308.46 | >336.58 | Normal |
| Leu+Ile | Leucine+Isoleucine | 172.56 | <201 | >215 | Normal |
| Met | Methionine | 19.67 | 6.97-24.8 | <6.34 , >28.5 | Normal |
| Orn | Ornithine | 75.26 | <182 | >202 | Normal |
| Phe | Phenylalanine | 52.02 | <68 | >109 | Normal |
| Pro | Proline | 230.34 | <374 | >404 | Normal |
| Tyr | Tyrosine | 1185.51 | <292.74 | >336.58 | * |
| Val | Valine | 152.32 | <131 | >143 | * |
| C0 | Free Carnitine | 37.080 | 7.14-43.34 | <5.6, 48 | Normal |
| C2 | Acetylcarnitine | 25.997 | 5.92-40.68 | <3.95, >45.29 | normal |
| C3 | Propionylcarnitine | 3.933 | 0.37-4.30 | <0.31 , >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.113 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.369 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.177 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.274 | <0.39 | >0.47 | Normal |
| C5:1 | Tiglylcarnitine | 0.019 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.325 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.048 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.238 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.040 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.096 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.039 | <0.139 | >0.16 | Normal |

| | | | | |
|------------------------------|------------------------------|-----------------|--------------|--------------------------------|
| شماره آزمایشگاه : L010508814 | نام : لیانا رستمی نصیرآباد | جنس : زن | OPD | تاریخ پذیرش : ۱۴۰۱/۰۵/۱۵ ۰۸:۵۷ |
| کد برگه : ۲۴۷۸۶۹۵ | نام پدر : مرتضی | سن : ۴.۴ ماه | تاریخ جواب : | ۱۴۰۱/۰۵/۲۳ ۱۲:۲۹ |
| کد پذیرش : ۵۶۹۴۲۲۴ | پزشک معالج : دکتر طالع - علی | نوع بیمه : آزاد | تاریخ چاپ : | ۱۴۰۲/۰۶/۰۶ ۱۴:۳۸ |

HPLC

| Test | Result | Unit | Reference Value |
|---------------------|--------------|---------------|-----------------|
| Aspartic Acid | 2.9 | uMol/L | 0-20 |
| Glutamic Acid | 87.4 | uMol/L | 10-120 |
| Asparagine | 38.2 | uMol/L | 24-60 |
| Serine | 142.3 | uMol/L | 60-200 |
| Glutamine | 679.8 | uMol/L | 396-746 |
| Histidine | 53.7 | uMol/L* | 50-130 |
| Glycine | 159.0 | uMol/L | 140-490 |
| Threonine | 92.4 | uMol/L | 40-240 |
| Citrulline | 20.9 | uMol/L | 8-47 |
| Arginine | 51.9 | uMol/L | 40-160 |
| Taurine | 31.7 | uMol/L | 19-216 |
| Alanine | 188.6 | uMol/L | 240-600 |
| Tyrosine | 387.4 | uMol/L | 30-120 |
| α-Aminobutyric Acid | 29.2 | uMol/L | 6-38 |
| Tryptophane | 70.7 | uMol/L | 15-73 |
| Methionine | 19.0 | uMol/L | 6-49 |
| Valin | 167.0 | uMol/L | 140-350 |
| Phenylalanine | 50.8 | uMol/L | 30-80 |
| Isoleucine | 53.2 | uMol/L | 30-130 |
| leucine | 76.2 | uMol/L | 60-230 |
| Ornithine | 42.2 | uMol/L | 20-135 |
| Lysine | 96.5 | uMol/L | 80-250 |

* Rechecked

Dr Signature :



Navigation icons and sidebar controls

| | |
|--|---|
|  <h2 style="text-align: center;">Urine Organic Acid Analysis</h2> <p style="text-align: center;">Growth And Development Research center Iran Metabolic Center</p> | <p>Document Number: HD-IMC-LA-RS-01-052263</p> <p>date:01/05/19</p> |
|--|---|

Name of Lab Center: Iran Metabolic Center
Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

| | | |
|---|---------------------------------|---|
| Patient's name: Liana Rostami nasir abad | Lab number: 8814 | Patient's ID: 012010518000325014022263 |
| Sample type: urine | Gender: female | age: 3m,25d |
| Physician/referred by: cmc | Reception Date: 01/05/18 | Reporting date: 01/05/19 |

Result:

| Abnormal Compound | Cut off | measure |
|-----------------------------|---------|----------|
| 4-Hydroxyphenyllactic acid | 12.51% | 2683.98% |
| 4-Hydroxyphenylacetic acid | 139.99% | 450.46% |
| 4-Hydroxyphenylpyruvic acid | 1.90% | 348.46% |

Comment:

The urine organic acid analysis shows significantly increased level of 4-Hydroxyphenyllactic acid, 4-Hydroxyphenylacetic acid and 4-Hydroxyphenylpyruvic acid, that is related to Tyrosinemia Type II. This patient is a known case of Tyrosinemia Type II.

Follow-up testing for elevated glycine

- *Possible diagnosis: NKH (nonketotic hyperglycinemia)*
- CSF amino acids - elevated glycine
- Plasma amino acids - elevated glycine
- Urine organic acids - rules out other metabolic causes for elevated glycine
- Confirmation:
 - Ratio of CSF: plasma glycine > 0.08
 - Reduced activity of the glycine cleavage system (liver)

Follow-up testing for elevated proline

- *Possible diagnosis: hyperprolinemia type I or type II*
- Plasma amino acids - elevated proline
- Urine organic acids (to rule out lactic acidosis and check for P5C)
- Confirmation:
 - Type II - P5C dehydrogenase deficiency - by marked elevation of D1-pyrroline 5-carboxylate (P5C) in urine and plasma
 - Type I - proline oxidase deficiency - by exclusion of type II

Follow-up testing for elevated methionine

- *Possible diagnosis: homocystinuria or hypermethioninemia*
- Plasma amino acids - elevated methionine and/or total plasma homocysteine
- Confirmation:

Cystathionine β -synthase activity in lymphocytes or fibroblasts (if Hcys and Met elevated)

- Methionine adenosyl transferase activity (if Met only elevated) in liver

Potential for false negatives MET

Transfusions

Delays in transit / sample deterioration

Physiological reasons

Potential for false positives :

Liver disease (for example due to tyrosinaemia type I or galactosaemia), parenteral nutrition, and methionine adenosyl transferase (MAT) deficiency can give rise to an elevated methionin concentration in the newborn period.

Homocystinuria

- Metab.: ↑ Hcy; more common: ↑ Met (2nd tier Hcy from DBS, where available)
- **Abnormal Screen Result: Elevated MET**
- Elevated MET/PHE
- DD: Liver failure (↑ Met and Tyr); MAT I/III (↑ Met only)
- Confirm.: AA plasma, Hcy
- Neonatal Presentation: None

- Homocystinuric patients can be sub-divided into **two** important biochemical phenotypes:
- Pyridoxine responsive (screen **undetectable**)
- Pyridoxine unresponsive (screen **detectable**)

Raised total homocysteine concentrations are also seen in some rarer inborn errors of metabolism (**MTHFR deficiency and defects of vitamin B12 metabolism**) and in **maternal B12 deficiency** but these would not be detected by screening as they are associated with **low**, rather than high, **methionine** concentrations.

Total homocysteine (tHcy)

- Blood should be centrifuged within **45 min** to obtain EDTA or heparin plasma or serum. For exact

measurement it is important to treat plasma or serum with a reducing agent that converts all Hcy species into the reduced form, HcyH, which is measured either directly or after derivatisation.

- *Normal values (fasting)*: children < 10 yrs: **3.5–9** $\mu\text{mol/l}$; > 10 yrs: **4.5–11** $\mu\text{mol/l}$; women premenopausal **6–15** $\mu\text{mol/l}$; post-menopausal **6–19** $\mu\text{mol/l}$; men **8–18** $\mu\text{mol/l}$.

Maple syrup urine disease

- Metab.: \uparrow XLE (= Leu + Ile + Allo-Ile + OH-Pro), \uparrow Val, \uparrow XLE/Ala
- **Abnormal Screen Result:**
 - Elevated LEU+ILE**
 - Elevated VAL
 - Elevated LEU+ILE/PHE
 - Elevated VAL/PHE
 - DD: Total parenteral nutrition, **hydroxyprolinaemia**, probably non-disease
 - Confirm.: AA plasma (Allo-Ile)

Pre-analytical aspects MSUD

- **Potential for false negatives**

Delays in transit / sample deterioration

Physiological reasons

transfusions

- **Potential for false positives :**

MS/MS analysis does not differentiate leucine from isoleucine or hydroxyproline. While elevation of leucine and isoleucine both result from MSUD, increased hydroxyproline may indicate the rare benign condition hydroxyprolinaemia.

increased leucine concentration in **galactosaemia** or other **severe liver disease**

تفسیر آزمایشات متابولیک





Figure 84-1. Clinical approach to a newborn infant with a suspected metabolic disorder. This schema is a guide to the elucidation of some of the metabolic disorders in newborn infants. Although some exceptions to this schema exist, it is appropriate for most cases.

Organic acidemias

| Disorders | Primary metabolite in MS/MS | Confirmatory tests / follow-up | Findings in confirmatory tests |
|---|--|--------------------------------|---|
| Glutaric aciduria 1 (GA I) | ↑ Glutaryl carnitine (C5-dicarboxylic) | UOA, PACP | ↑ Glutaric acid, 3-hydroxyglutaric acid, glutaconic acid on UOA; ↑ Glutaryl carnitine (C5-dicarboxylic) on PACP |
| HMG- CoA lyase deficiency | ↑ 3- Hydroxyisovalerylcarnitine (C5-OH) | UOA, PACP | ↑ 3-Hydroxyisovaleric, 3-methylglutaconic, 3-methylglutaric, 3-hydroxy-3-methylglutaric acids on UOA; ↑ C5- Hydroxyisovalerylcarnitine (C5-OH), 3 methylglutaryl carnitine (C6DC) on PACP |
| Isovaleric acidemia | ↑ Isovalerylcarnitine (C5) | UOA, PACP | ↑ Isovalerylglycine, 3-hydroxyisovaleric acid on UOA; ↑ isovalerylcarnitine (C5) on PACP |
| 3-Keto(oxo) thiolase deficiency | ↑ Tiglylcarnitine (C5:1), ↑ 3-hydroxy-2-methylbutyrylcarnitine (C5-OH) | UOA, PACP | ↑ 2-Methyl-3- hydroxybutyrate, 2 methylacetoacetic, tiglylglycine on UOA; ↑ tiglylcarnitine (C5:1), ↑ 3-hydroxy-2-methylbutyrylcarnitine (C5-OH) on PACP |
| 3-MCC deficiency | ↑ 3- Hydroxyisovalerylcarnitine (C5-OH) | UOA, PACP | ↑ 3-Hydroxyisovaleric, 3-methylcrotonylglycine on UOA; ↑ 3- hydroxyisovalerylcarnitine (C5-OH) on PACP |
| 2-Methylbutyryl CoA dehydrogenase | ↑ 2-Methylbutyrylcarnitine (C5) | UOA | ↑ 2-Methylbutyrylglycine on PACP |
| 3-Methylglutanoyl CoA hydratase deficiency | ↑ 3 Hydroxyisovalerylcarnitine (C5-OH) | UOA, PACP | ↑ 3-Hydroxyisovaleric, 3-methylglutaconic, 3-methylglutaric on UOA; ↑ 3 hydroxyisovalerylcarnitine (C5-OH) on PACP |
| Methylmalonic acidemia | ↑ Propionyl carnitine (C3) | UOA, PACP | Methylmalonic, 3-hydroxypropionate, methylcitrate, propionylglycine on UOA; ↑ propionyl carnitine (C3) on PACP |
| Multiple CoA carboxylase deficiency | ↑ Propionyl carnitine (C3), ↑ 3-hydroxyisovalerylcarnitine (C5-OH) | UOA, PACP | ↑ 3-OH-isovaleric, 3-methylcrotonylglycine, methylcitrate, 3-OH-propionic, lactate, pyruvate, acetoacetate, 3-OH-butyrate on UOA; ↑ propionyl carnitine (C3), ↑ 3 hydroxyisovalerylcarnitine (C5-OH) on PACP |
| Propionic acidemia | ↑ Propionyl carnitine (C3) | UOA, PACP | ↑ 3-Hydroxypropionate, methylcitrate, propionylglycine; ↑ propionyl carnitine (C3) on PACP |



□ Acylcarnitine profile is helpful:

❖ ↑ **C₃** (propionyl carnitine) → *P.A

*MMA

*MCD

❖ ↑ **C₅** (Isovaleryl carnitine): IVA

❖ ↑ **C₅OH** (3-hydroxy isovaleryl carnitine) →

- BKT
- MCD
- MCC
- HMGL
- IVA
- 2M-3HBA

❖ ↑ **C₄DC** (Methyl malonyl carnitine): MMA

❖ ↑ **C₅DC** (Glutaryl carnitine): GA₁

Acylcarnitines in Organic Acidemias: Primary Markers

- Acylcarnitine species Disorder to be considered
- C3 PA, MMA, MCD
- C4 IBCD, (SCAD, MAD)
- C5 IVA, 2MBCD ,(MAD)
- C5:1 (with C5-OH) SKAT, 3-MCC
- C5-OH 3-MCC, HMGL, SKAT, MCD, 3-methylglutaconyl hydratase def
- C3-DC MA
- C5-DC GA-I,
- C6-DC (with C5-OH) HMG

❖ **Urine organic acid analysis is diagnostic for differentiation:**

P.A →

- MC
- PG
- 3HPA

❖ **MMA** →

- MC
- PG
- MMA
- 3HPA

❖ **MCD** →

- MC
- 3HPA
- methyl crotonylglycine

- ❖ **Biotinidase deficiency** →
 - ↓ Biotinidase enzyme
 - GCMS: ↑ MCG- 3HPA- MC

- ❖ **IVA** → ↑ IVG

- ❖ **BKT**: 2M 3HBA, TG

- ❖ **GA₁**: GA, 3HGA

- ❖ **HMGL**: 3-hydroxy 3-methylglutaric acid,
3-methylglutaconic acid

- ❖ **MSUD** →
 - HPLC, MS/MS : ↑ leucine, valine, isoleucine
 - U.GCMS: ↑ ketoisovalerate, α keto
3-methylvalerate, α ketoisocaproate

- Elevated C3 (C3/C0, C3/C2, C4DC)
- Abnormal Screen Result: Elevated C3 (propionyl carnitine)
- Elevated C3/C2 Elevated C3/C16
- when the C3 is greater than **10 μM** and the **C3/C2** and/or **C3/C16** is elevated or when the C3 is greater than **15 μM** , regardless of the ratio levels
- **DD:** Propionic aciduria ,methylmalonic aciduria; cobalamin disorders, FIGLU(Glutamate formiminotransferase deficiency),Succinyl CoA synthase deficiency
- many false positive cases
- Confirm.: Acylcarnitines (plasma), OA (urine)

| | | | | | |
|-------------|--|--------|------------|---------------|--------|
| Phe | Phenylalanine | 20.15 | <68 | >109 | Normal |
| Pro | Proline | 128.72 | <374 | >404 | Normal |
| Tyr | Tyrosine | 34.36 | <292.74 | >336.58 | Normal |
| Val | Valine | 58.60 | <131 | >143 | Normal |
| C0 | Free Carnitine | 11.922 | 7.14-43.34 | <5.6, 48 | Normal |
| C2 | Acetylcarnitine | 12.743 | 5.92-40.68 | <3.95, >45.29 | normal |
| C3 | Propionylcarnitine | 20.304 | 0.37-4.30 | <0.31 , >5 | * |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.105 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.116 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | ethylmalonylcarnitine & Hydroxyisovalerylcarnit | 0.229 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.081 | <0.39 | >0.47 | Normal |
| C5:1 | Tiglylcarnitine | 0.051 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutarylcarnitine & Hydroxyhexanoyr carnitine | 0.323 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.048 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutarylcarnitine | 0.184 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.024 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.014 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.020 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.016 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.008 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.025 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.008 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.090 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.016 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.006 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.002 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 1.000 | 0.41-6.09 | <0.33 , >7.13 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.005 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.040 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylecarnitine | 0.046 | <0.11 | >0.134 | Normal |
| C18 | Octadecanoylcarnitine | 0.577 | 0.19-1.71 | <0.16 , >1.89 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.814 | 0.32-2.33 | <0.27 , >2.55 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.325 | 0.059-0.56 | <0.05 , >0.66 | Normal |
| C18:1OH | Hydroxyoctadecenoylecarnitine | 0.011 | <0.07 | >0.14 | Normal |
| C18:2OH | Hydroxylinoleoylecarnitine | 0.008 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylecarnitine | 0.003 | <0/022 | >0/11 | Normal |

| Qty | Quantity | Value | Unit | Reference | Normal |
|-------------|---|--------|-----------|---------------|--------|
| Leu+Ile | Leucine+Isoleucine | 43.04 | <201 | >252 | Normal |
| Met | Methionine | 6.89 | 6.97-22 | <4.90, >31 | * |
| Orn | Ornithine | 36.25 | <177 | >193 | Normal |
| Phe | Phenylalanine | 14.96 | <64 | >111 | Normal |
| Pro | Proline | 116.16 | <351 | >371 | Normal |
| Tyr | Tyrosine | 28.74 | <120 | >401 | Normal |
| Val | Valine | 30.63 | <131 | >171 | Normal |
| C0 | Free Carnitine | 9.612 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 17.225 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 13.234 | 0.38-4.24 | <0.27, >5.82 | * |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.219 | <0.17 | >0.38 | * |
| C4 | Butyrylcarnitine | 0.070 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.272 | <0.19 | >0.78 | * |
| C5 | Isovalerylcarnitine | 0.049 | <0.39 | >0.57 | Normal |
| C5:1 | Tiglylcarnitine | 0.069 | <0.08 | >0.33 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoylcarnitine | 0.345 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.039 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 0.245 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.027 | <0.10 | >0.37 | Normal |
| C8:1 | Octenoylcarnitine | 0.017 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.028 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.020 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.006 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.021 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.012 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.073 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.017 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.009 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.002 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.994 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.005 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.042 | <0.31 | >0.32 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.042 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.550 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.762 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.287 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.012 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.010 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.002 | <0/022 | >0/063 | Normal |

10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0

Result


| | Compound Name | Cut-off | measure | Error |
|-----|----------------------------------|---------|----------|-------|
| 11 | 3-Hydroxybutyric acid-2TMS | 5/28% | 6256/46% | * |
| 3 | Caproic acid-TMS | 0/50% | 0/99% | * |
| 68 | Adipic acid-2TMS | 13/00% | 23/65% | * |
| 1 | Lactic acid-2TMS | 6/70% | 36/22% | * |
| 22 | 2-Hydroxyisocaproic acid-2TMS | 0/50% | 90/23% | * |
| 14 | 2-Methyl-3-hydroxybutyric acid-2 | 7/65% | 45/95% | * |
| 97 | Suberic acid-2TMS | 11/51% | 11/71% | * |
| 17 | 2-Keto-isovaleric acid-oxime-2TM | 0/50% | 0/71% | * |
| 59 | 3-Methylglutaconic acid(E)-2TMS | 5/12% | 15/01% | * |
| 110 | Methylcitric acid-4TMS | 1/81% | 23/91% | * |
| 112 | Methylcitric acid-4TMS | 1/49% | 10/00% | * |
| 77 | Tiglylglycine-2TMS | 0/50% | 436/62% | * |
| 79 | Tiglylglycine-TMS | 0/53% | 99/30% | * |
| 4 | Glycolic acid-2TMS | 3/99% | 8/94% | * |
| 21 | 4-Hydroxybutyric acid-2TMS | 0/50% | 75/53% | * |
| 55 | Propionylglycine-2TMS | 0/50% | 38/23% | * |
| 5 | Oxalic acid-2TMS | 1/00% | 9/46% | * |
| 62 | decanoic-1 | 0/50% | 0/68% | * |
| 78 | 3-Methylcrotonoylglycine-TMS | 1/05% | 2/38% | * |
| 8 | 3-Hydroxypropionic acid-2TMS | 1/95% | 686/19% | * |
| 27 | Acetoacetic acid-oxime-2TMS | 0/10% | 282/62% | * |
| 75 | 7-Hydroxooctanoic acid-2TMS | 0/06% | 6/58% | * |
| 89 | 4-Hydroxyphenylacetic acid-2TMS | 139/99% | 200/50% | * |
| 23 | 3-Hydroxyvaleric acid-2TMS | 0/50% | 359/46% | * |
| 16 | 3-Hydroxyisovaleric acid-2TMS | 6/10% | 37/49% | * |
| 123 | Palmitic acid TMS | 23/34% | 78/24% | * |
| 44 | Propionylglycine-TMS | 0/50% | 19/10% | * |
| 36 | Acetylglucine-TMS | 0/50% | 20/41% | * |
| 19 | 2-ethyl-3-OH-propionic-2TMS | 6/22% | 14/17% | * |
| 6 | 2-Hydroxybutyric acid-2TMS | 0/50% | 4/16% | * |
| 43 | Fumaric acid-2TMS | 10/36% | 20/20% | * |
| 38 | Maleic acid-2TMS | 0/55% | 4/69% | * |
| 30 | 2-Methyl-3-hydroxyvaleric acid-2 | 0/50% | 1/79% | * |
| 56 | Isobutyrylglycine-2TMS | 0/50% | 0/57% | * |
| 67 | Malic acid-3TMS | 1/20% | 2/74% | * |

Methylmalonic Acidemia with Homocystinuria (CBL C, D, F)

- Abnormal Screen Result: Elevated **C3** (propionyl carnitine)
- Decreased **MET** (Methionine)
- Elevated **C3/C2**

Ex1) elevation of C3 in tandem MS

Methylmalonicacidemia



Elevated C5 (C5/C2)

(isovaleryl carnitine) Isovaleric acidemia is a disorder of **leucine** (LEU)

DD: Isovaleric aciduria ,2-methylbutyric aciduria ,possibly non-disease,

- Confirm: Acylcarnitines plasma, OA urine
- In OA:Lactic, 3OH-BUTYRIC, **ISOVALERYLGLYCINE**, HIPPURIC, CITRIC, ISOVALERYLGLUTAMATE



| | | | | | |
|-------------|---|--------|------------|---------------|--------|
| Pro | Proline | 137.46 | <3/4 | >404 | Normal |
| Tyr | Tyrosine | 74.06 | <292.74 | >336.58 | Normal |
| Val | Valine | 63.55 | <131 | >143 | Normal |
| C0 | Free Carnitine | 20.698 | 7.14-43.34 | <5.6, 48 | Normal |
| C2 | Acetylcarnitine | 18.350 | 5.92-40.68 | <3.95, >45.29 | normal |
| C3 | Propionylcarnitine | 3.352 | 0.37-4.30 | <0.31, >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.074 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.196 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | ethylmalonylcarnitine & Hydroxyisovalerylcarnit | 0.169 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 2.448 | <0.39 | >0.47 | * |
| C5:1 | Tiglylcarnitine | 0.044 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.350 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.044 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.266 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.043 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.031 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.047 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.045 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.008 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.046 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.027 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.152 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.055 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.013 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.006 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 3.154 | 0.41-6.09 | <0.33, >7.13 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.013 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.137 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.043 | <0.11 | >0.134 | Normal |
| C18 | Octadecanoylcarnitine | 1.126 | 0.19-1.71 | <0.16, >1.89 | Normal |
| C18:1 | Octadecenoylcarnitine | 1.511 | 0.32-2.33 | <0.27, >2.55 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.161 | 0.059-0.56 | <0.05, >0.66 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.017 | <0.07 | >0.14 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.008 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.013 | <0/022 | >0/11 | Normal |

| | | | | | |
|-------------|---|--------|-----------|---------------|--------|
| C0 | Free Carnitine | 15.335 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 5.538 | 6.2-40.5 | <4.3, >44.8 | * |
| C3 | Propionylcarnitine | 0.569 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.029 | <0.17 | >0.38 | Normal |
| C4 | Butyrylcarnitine | 0.075 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.100 | <0.19 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.981 | <0.39 | >0.57 | * |
| C5:1 | Tiglylcarnitine | 0.028 | <0.08 | >0.33 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.175 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.030 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 0.228 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.039 | <0.10 | >0.37 | Normal |
| C8:1 | Octenoylcarnitine | 0.063 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.049 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.052 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.013 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.027 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.020 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.039 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.027 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.014 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.003 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.543 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.004 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.026 | <0.31 | >0.32 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.022 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.385 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.401 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.129 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.006 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.004 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.004 | <0/022 | >0/063 | Normal |



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-LA-RS-00-081883

date:00/08/18

Name of Lab Center: Iran Metabolic Center
Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

| | | |
|--------------------------------------|-------------------------|---------------------------------------|
| Patient's name: Elena Mirzamohammadi | Lab number:8532 | Patient's ID:012000817000010014021883 |
| Sample type: urine | Gender: female | age:10d |
| Physician/referred by: CMC | Reception Date:00/08/17 | Reporting date: 00/08/18 |


Result:

| Abnormal Compound | Cut off | measure |
|---------------------|---------|---------|
| isovalerylglycine-1 | 0.69% | 11.82% |


Comment:

The urine organic acid analysis shows increased level of isovalerylglycine. That is indicative of isovaleric acidemia.

Isovaleric acidemia



Isobutyryl-CoA dehydrogenase deficiency



Pre-analytical aspects C5

- **Potential for false negatives :**

Transfusions

Delays in transit / sample deterioration

Physiological reasons

- **Potential for false positives :**

Pivaloylcarnitine is **isobaric** with isovaleryl carnitine and can result in false positive results

pivalic derivatives present in nipple creams and **AB**

Glutaric aciduria type 2 is often associated with an increase in **C5, C8 and C5-DC**

2-methylbutyryl carnitine is elevated in short/branched chain acyl-CoA dehydrogenase deficiency (SBCAD), 2-methyl butyryl co A dehydrogenase deficiency and is isobaric with isovalerylcarnitine and causes a positive screening result

OA:**2-METHYLBUTYRYLGLYCINE**, 2-ETHYL-3OH-PROPIONIC, ALPHA-KG, HIPPURIC, CITRIC



| | | | | | |
|-------------|---|--------|------------|----------------|--------|
| Arg | Arginine | 14.76 | 3.39-51.31 | <2.80 , >62.07 | Normal |
| Cit | Citrulline | 9.55 | 5.2-27 | <3 , >50 | Normal |
| Glu | Glutamic Acid | 493.01 | <593 | >723 | Normal |
| Gly | Glycine | 83.47 | <308.46 | >336.58 | Normal |
| Leu+Ile | Leucine+Isoleucine | 88.44 | <201 | >215 | Normal |
| Met | Methionine | 10.19 | 6.97-24.8 | <6.34 , >28.5 | Normal |
| Orn | Ornithine | 55.35 | <182 | >202 | Normal |
| Phe | Phenylalanine | 28.01 | <68 | >109 | Normal |
| Pro | Proline | 136.65 | <374 | >404 | Normal |
| Tyr | Tyrosine | 64.40 | <292.74 | >336.58 | Normal |
| Val | Valine | 54.35 | <131 | >143 | Normal |
| C0 | Free Carnitine | 25.362 | 7.14-43.34 | <5.6 , 48 | Normal |
| C2 | Acetylcarnitine | 16.150 | 5.92-40.68 | <3.95 , >45.29 | normal |
| C3 | Propionylcarnitine | 1.539 | 0.37-4.30 | <0.31 , >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.049 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.154 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.177 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.712 | <0.39 | >0.47 | * |
| C5:1 | Tiglylcarnitine | 0.024 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.149 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.068 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.142 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.047 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.076 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.055 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.032 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.007 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.046 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.016 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.136 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.034 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.007 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.004 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 1.998 | 0.41-6.09 | <0.33 , >7.13 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.009 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.067 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.133 | <0.11 | >0.134 | * |
| C18 | Octadecanoylcarnitine | 1.284 | 0.19-1.71 | <0.16 , >1.89 | Normal |



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-
LA-RS-001-083325

date:01/08/28

Address of Lab Center: Iran Metabolic Center

Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical
Center, 62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

Patient's name: Mohamadtaha Abdi

Lab number:15737

Patient's ID:012010825000105014023325

Sample type: urine

Gender: male

age:1m, 5d

Physician/referred by: CMC

Reception Date:01/08/25

Reporting date: 01/08/28

Result:

| Abnormal Compound | Cut off | measure |
|-------------------|---------|---------|
| - | - | - |

2 methylbutyrylglycine

Comment:

No distinct abnormality was seen.

Search 'Comp

Export

Adobe Export

Convert PDF File
or Excel Online

Select PDF File

Mohamadtaha

Convert to

Microsoft Word

Document Lang
English (U.S.) C

Con

Edit PD

Create

Comm

Follow-up testing for elevated C5

- *Possible diagnosis: isovaleryl-coA dehydrogenase deficiency, 2-methylbutyryl-coA dehydrogenase deficiency (2-MBCD), multiple acyl-coA dehydrogenase (MAD deficiency)*
- **Plasma acylcarnitine analysis - elevated C5 (+ others in MAD deficiency)**

Follow-up testing for elevated C5-DC

- *Possible diagnosis: Glutaryl-coA dehydrogenase deficiency (GA-I) (Glutaric aciduria type 1)*
- Metab.: ↑ C5DC (= glutaryl-CoA)
- Elevated C5DC (glutaryl carnitine) + C6OH (3-OH hexanoyl carnitine)

Urine OA analysis - glutaric acidemia "classical": 3OH-GLUTARIC, GLUTARIC

- Urine organic acids analysis - glutaric acidemia "low excretor" - glutaric acid not observed! :3OH-GLUTARIC

Pre-analytical aspects C5-DC

- **Potential for false negatives :**

Transfusions

Delays in transit / sample deterioration

Physiological reasons

- **Potential for false positives :**



C6OH acylcarnitine is **isobaric** with C5-DC acylcarnitine

- elevated C6OH acylcarnitine is seen in association with **ketosis**

Glutaric aciduria type 2 is often associated with an increase in C5, C8 and C5-DC acylcarnitines,

Glutaric acidemia type I

Short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency (also known as 2-methylbutyryl-CoA dehydrogenase)



Elevated C5OH+C4DC

- **Elevated C5OH & C4DC** (methyl malonyl carnitine)
- **DD:1.** Multiple carboxylase deficiency, **C3 Elevate**
- **2.** HMG-CoA lyase deficiency, also **↑ C6DC**
- **3.** 3-Methylcrotonylglycinuria (3MCC) (possibly non-disease)
Maternal 3-MCC: In some newborns, the elevated C4DC+C5OH is reflective of maternal 3-MCC levels.
- **4.** 3-Methylglutaconic aciduria I (probably non-disease in childhood) also **C6:1**
- **5.** 3-Oxothiolase deficiency, also **↑ C5:1**
- **Confirm.:** Acylcarnitines plasma, OA urine

| | | | | | |
|--------------|---|--------|-----------|--------------|--------|
| C2 | Acetylcarnitine | 21.20 | 7-38 | <5, >40 | Normal |
| C3 | Propionylcarnitine | 2.06 | 0.3-4/6 | <0.3, >5/0 | Normal |
| C3DC & C8OH | Malonylcarnitine & 3-Hydroxyoctanoylcarnitine | 0.00 | <0/05 | >0/15 | Normal |
| C4 | Butyrylcarnitine | 0.24 | <0.55 | >0/75 | Normal |
| C4OH | Hydroxybutyrylcarnitine | 0.15 | <0.3 | >0.5 | Normal |
| C4DC | Methylmalonylcarnitine | 0.22 | <0/25 | >0.34 | Normal |
| C5 | Isovalerylcarnitine | 0.18 | <0.36 | >0.45 | Normal |
| C5DC & C10OH | Glutaryl carnitine & 3-Hydroxydecanoylcarnitine | 0.03 | <0/15 | >0.16 | Normal |
| C5:1 | Tiglylcarnitine | 0.04 | <0.03 | >0.09 | * |
| C5OH | Hydroxyisovalerylcarnitine | 7.01 | <0/27 | >0.47 | * |
| C6 | Hexanoylcarnitine | 0.03 | <0.09 | >0.12 | Normal |
| C6DC | Adipoylcarnitine | 0.01 | <0.05 | >0.06 | Normal |
| C8 | Octanoylcarnitine | 0.04 | <0.08 | >0.28 | Normal |
| C8:1 | Octenoylcarnitine | 0.05 | <0/18 | >0.19 | Normal |
| C10 | Decanoylcarnitine | 0.03 | <0.14 | >0.15 | Normal |
| C10:2 | Decadienoylcarnitine | 0.01 | <0.03 | >0.05 | Normal |
| C10:1 | Decenoylcarnitine | 0.04 | <0.12 | >0.17 | Normal |
| C12 | Dodecanoylcarnitine | 0.06 | <0.3 | >0.55 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.10 | <0.2 | >0.3 | Normal |
| C14 | Tetradecanoylcarnitine | 0.14 | <0/35 | >0.55 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.01 | <0.05 | >0.08 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.04 | <0.17 | >0.31 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.01 | <0/03 | >0/04 | Normal |
| C16 | Hexadecanoylcarnitine | 2.28 | 0/55-7/08 | <0/55, >8/68 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.15 | <0/47 | >0.51 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.04 | <0/14 | >0.15 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.01 | <0.05 | >0.14 | Normal |
| C18 | Octadecanoylcarnitine | 0.84 | 0.22-1/67 | <0.2, >1.9 | Normal |
| C18:2 | Octadecadienoylcarnitine | 0.43 | 0/07-0/68 | <0.07, >0/82 | Normal |
| C18:1 | Octadecenoylcarnitine | 1.56 | 0/35-2/5 | <0.2, >2.76 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.0363 | <0/09 | >0/1 | Normal |
| C18:1OH | Hydroxyoleoylcarnitine | 0.0201 | <0/04 | >0.05 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.0201 | <0/03 | >0.05 | Normal |

| | | | | | |
|--------------|---|---------|-----------|----------------|--------|
| C2 | Acetylcarnitine | 5.92 | 7-38 | <5, >40 | * |
| C3 | Propionylcarnitine | 0.64 | 0.3-4/6 | <0.21 , >6 | Normal |
| C3DC & C8OH | Malonylcarnitine & 3-Hydroxyoctanoylcarnitine | 0.01 | <0/05 | >0/15 | Normal |
| C4 | Butyrylcarnitine | 0.09 | <0.55 | >0/862 | Normal |
| C4OH | Hydroxybutyrylcarnitine | 0.04 | <0.3 | >0.64 | Normal |
| C4DC | Methylmalonylcarnitine | 0.17 | <0/25 | >0.5 | Normal |
| C5 | Isovalerylcarnitine | 0.09 | <0.36 | >0.54 | Normal |
| C5DC & C10OH | Glutaryl carnitine & 3-Hydroxydecanoylcarnitine | 0.01 | <0/15 | >0.16 | Normal |
| C5:1 | Tiglylcarnitine | 0.02 | <0.03 | >0.143 | Normal |
| C5OH | Hydroxyisovalerylcarnitine | 12.60 | <0/27 | >0.6 | * |
| C6 | Hexanoylcarnitine | 0.00 | <0.09 | >0.16 | Normal |
| C6DC | Adipoylcarnitine | 0.01 | <0.05 | >0.087 | Normal |
| C8 | Octanoylcarnitine | 0.01 | <0.08 | >0.34 | Normal |
| C8:1 | Octenoylcarnitine | 0.02 | <0/18 | >0.19 | Normal |
| C10 | Decanoylcarnitine | 0.01 | <0.14 | >0.18 | Normal |
| C10:2 | Decadienoylcarnitine | 0.00 | <0.03 | >0.07 | Normal |
| C10:1 | Decenoylcarnitine | 0.01 | <0.12 | >0.22 | Normal |
| C12 | Dodecanoylcarnitine | 0.02 | <0.3 | >0.75 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.10 | <0.2 | >0.39 | Normal |
| C14 | Tetradecanoylcarnitine | 0.04 | <0/35 | >0.64 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.01 | <0.05 | >0.11 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.02 | <0.17 | >0.36 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.01 | <0/03 | >0/04 | Normal |
| C16 | Hexadecanoylcarnitine | 0.44 | 0/55-7/08 | <0/324 , >10 | * |
| C16:1 | Hexadecenoylcarnitine | 0.02 | <0/47 | >0.51 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.01 | <0/14 | >0.19 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.00 | <0.05 | >0.2 | Normal |
| C18 | Octadecanoylcarnitine | 0.22 | 0.22-1/67 | <0.142 , >2.18 | Normal |
| C18:2 | Octadecadienoylcarnitine | 0.25 | 0/07-0/68 | <0.046 , >1.08 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.31 | 0/35-2/5 | <0.156 , >3.09 | * |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.019 | <0/09 | >0/1 | Normal |
| C18:1OH | Hydroxyoleoylcarnitine | 0.00527 | <0/04 | >0.07 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.00527 | <0/03 | >0.08 | Normal |



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-LA-RS-00071031

date:00/07/12

| | | |
|---|-------------------------|---------------------------------------|
| Name of Lab Center: Iran Metabolic Center | | |
| Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran | | |
| Telephone 021-61472434 | | Fax: 66949662 |
| Patient's name: Mohadese Hosseini | Lab number: | Patient's ID:012000710000017014041031 |
| Sample type: urine | Gender: female | age:17d |
| Physician/referred by: CMC | Reception Date:00/07/10 | Reporting date: 00/07/12 |

Result:

| Abnormal Compound | Cut off | measure |
|--------------------------|---------|---------|
| 3-Methylcrotonoylglycine | 0.52% | 209.69% |
| 3-Hydroxyisovaleric acid | 6.10% | 559.14% |

Comment:

The urine organic acid analysis shows increased level of 3-Methylcrotonoylglycine and 3-Hydroxyisovaleric acid. That is indicative of 3-Methylcrotonyl-CoA Carboxylase Deficiency (3-MCC). Enzyme assay and genetic study is recommended, for definitive diagnosis. Maternal 3-Methylcrotonyl-CoA Carboxylase Deficiency should also be considered.

Follow-up testing for elevated C5-OH (3-OH isovaleryl carnitine)

- Plasma acylcarnitine analysis –
- elevated C5-OH; also with **C5:1** in **3-MCC** and **SKAT**,
- or with **C6DC** in **HMG**;
- or with **C3** (propionyl carnitine) in **MCD** (holocarboxylase synthetase def).

| | | | | | |
|--------------|---|--------|-----------|---------------|--------|
| Orn | Ornithine | 99.50 | <133 | >148 | Normal |
| Phe | Phenylalanine | 49.60 | <69 | >112 | Normal |
| Pro | Proline | 304.00 | <292 | >314 | * |
| Tyr | Tyrosine | 35.50 | <264 | >303 | Normal |
| Val | Valine | 164.00 | <156 | >166 | * |
| C0 | Free Carnitine | 29.50 | 8/0-40 | <6/5 , >45 | Normal |
| C2 | Acetylcarnitine | 35.10 | 7-38 | <5 , >40 | Normal |
| C3 | Propionylcarnitine | 2.26 | 0.3-4/6 | <0.3 , >5/0 | Normal |
| C3DC & C8OH | Malonylcarnitine & 3-Hydroxyoctanoylcarnitine | 0.03 | <0/05 | >0/15 | Normal |
| C4 | Butyrylcarnitine | 0.30 | <0.55 | >0/75 | Normal |
| C4OH | Hydroxybutyrylcarnitine | 0.14 | <0.3 | >0.5 | Normal |
| C4DC | Methylmalonylcarnitine | 0.17 | <0/25 | >0.34 | Normal |
| C5 | Isovalerylcarnitine | 0.26 | <0.36 | >0.45 | Normal |
| C5DC & C10OH | Glutaryl carnitine & 3-Hydroxydecanoylcarnitine | 0.22 | <0/15 | >0.16 | * |
| C5:1 | Tiglylcarnitine | 0.02 | <0.03 | >0.09 | Normal |
| C5OH | Hydroxyisovalerylcarnitine | 3.22 | <0/27 | >0.47 | * |
| C6 | Hexanoylcarnitine | 0.08 | <0.09 | >0.12 | Normal |
| C6DC | Adipoylcarnitine | 0.18 | <0.05 | >0.06 | * |
| C8 | Octanoylcarnitine | 0.09 | <0.08 | >0.28 | * |
| C8:1 | Octenoylcarnitine | 0.07 | <0/18 | >0.19 | Normal |
| C10 | Decanoylcarnitine | 0.15 | <0.14 | >0.15 | * |
| C10:2 | Decadienoylcarnitine | 0.01 | <0.03 | >0.05 | Normal |
| C10:1 | Decenoylcarnitine | 0.06 | <0.12 | >0.17 | Normal |
| C12 | Dodecanoylcarnitine | 0.23 | <0.3 | >0.55 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.16 | <0.2 | >0.3 | Normal |
| C14 | Tetradecanoylcarnitine | 0.33 | <0/35 | >0.55 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.03 | <0.05 | >0.08 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.14 | <0.17 | >0.31 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.02 | <0/03 | >0/04 | Normal |
| C16 | Hexadecanoylcarnitine | 7.53 | 0/55-7/08 | <0/55 , >8/68 | * |
| C16:1 | Hexadecenoylcarnitine | 0.41 | <0/47 | >0.51 | Normal |
| C16:1OH | Hydroxyhexadecanoylcarnitine | 0.07 | <0/14 | >0.15 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.04 | <0.05 | >0.14 | Normal |
| C18 | Octadecanoylcarnitine | 1.89 | 0.22-1/67 | <0.2 , >1.9 | * |
| C18:2 | Octadecadienoylcarnitine | 0.38 | 0/07-0/68 | <0.07 , >0/82 | Normal |
| C18:1 | Octadecenoylcarnitine | 2.52 | 0/35-2/5 | <0.2 , >2.76 | * |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.062 | <0/09 | >0/1 | Normal |
| C18:1OH | Hydroxyoleoylcarnitine | 0.0361 | <0/04 | >0.05 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.0361 | <0/03 | >0.05 | * |

| Unit | Compound | Value | Reference Range | Reference Range | Reference Range |
|-------------|---|--------|-----------------|-----------------|-----------------|
| Leu+Ile | Leucine+Isoleucine | 148.83 | <201 | >252 | Normal |
| Met | Methionine | 14.55 | 6.97-22 | <4.90, >31 | Normal |
| Orn | Ornithine | 100.91 | <177 | >193 | Normal |
| Phe | Phenylalanine | 36.57 | <64 | >111 | Normal |
| Pro | Proline | 287.23 | <351 | >371 | Normal |
| Tyr | Tyrosine | 166.61 | <120 | >401 | * |
| Val | Valine | 130.54 | <131 | >171 | Normal |
| C0 | Free Carnitine | 20.673 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 7.432 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 0.483 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.029 | <0.17 | >0.38 | Normal |
| C4 | Butyrylcarnitine | 0.090 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 2.238 | <0.19 | >0.78 | * |
| C5 | Isovalerylcarnitine | 0.180 | <0.39 | >0.57 | Normal |
| C5:1 | Tiglylcarnitine | 0.087 | <0.08 | >0.33 | * |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoylcarnitine | 0.290 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.039 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 1.464 | <0.52 | >0.56 | * |
| C8 | Octanoylcarnitine | 0.068 | <0.10 | >0.37 | Normal |
| C8:1 | Octenoylcarnitine | 0.092 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.071 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.094 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.033 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.033 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.025 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.053 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.025 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.019 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.003 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 1.110 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.004 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.031 | <0.31 | >0.32 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.036 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.638 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.594 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.268 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.005 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.007 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.003 | <0/022 | >0/063 | Normal |



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-LA-RS-0010-3128

date:00/11/16

Name of Lab Center: Iran Metabolic Center
Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

| | | |
|-------------------------------|-------------------------|---------------------------------------|
| Patient's name: Karen Rezayat | Lab number:17374 | Patient's ID:012001030000019014043128 |
| Sample type: urine | Gender: male | age:19d |
| Physician/referred by: CMC | Reception Date:00/10/30 | Reporting date: 00/11/16 |

Result:

| Abnormal Compound | Cut off | measure |
|---------------------------------|---------|---------|
| Adipic acid | 13.00% | 14.64% |
| 4-Hydroxyphenyllactic acid | 12.51% | 31.71% |
| 3-Methylglutaconic acid(E) | 5.12% | 803.74% |
| Glutaric acid | 8.44% | 23.73% |
| 3-methylglutaconic-2(3) | 14.15% | 392.99% |
| Tiglylglycine | 0.53% | 9.10% |
| 3-Methylcrotonoylglycine | 1.05% | 3.60% |
| 3-Methylglutaconic acid | 0.50% | 10.58% |
| 3-Hydroxy-3-methylglutaric acid | 30.52% | 156.96% |

Urine organic acids analysis

- moderate or marked elevation of 3OH-isovalerate, with 3-methylcrotonylglycine(**3-MCC**);
or with 3-methylglutaconic and 3Methyl-3OH-glutaric acids , 3-METHYLGLUTARIC(**HMG**);
or with 3-methylglutaconic acid (**glutaconic aciduria type I**);
or with metabolites of propionic acidemia in **MCD**.
- In β -ketothioase deficiency (**SKAT**), there is marked elevation of 2-methyl-3-OH-butyric and 2-methylacetoacetic acids, with tiglylglycine.

Biotinidase deficiency

- Method: Determination of biotinidase activity (% normal); residual activity $< 10\%$ = **severe** deficiency,
- $10-20(-30)\%$ = **partial** deficiency
- Exposure of test card to humid heat may cause denaturation of enzymes and consecutively a **false positive** result
- Confirm.: Biotinidase analysis in serum/plasma

Beta Ketothiolase Deficiency

- Elevated **C4DC** (methyl malonyl carnitine) + **C5OH** (3-OH isovaleryl carnitine)
- **C5:1** Tiglyl- BKT, MCC, MHBD, MCD
- **C4-DC** Methylmalonyl-/succinyl- MMA a ,
SUCLA2
- In SUCLA2 C3 & C4DC Increase & methylmalonic
in OA

2-Methyl 3-OH Butyric Aciduria (2M3HBA)

- Elevated **C4DC** (methyl malonyl carnitine) + **C5OH** (3-OH isovaleryl carnitine)
- Elevated **C5:1** (tiglyl carnitine)
- Neonatal Presentation: Usually none

Elevated C4(butyryl carnitine)

- DD: **SCAD** deficiency ,**IBD** deficiency
(**Isobutyryl Glycinuria**)**Ethylmalonic Encephalopathy** also **C5**
- Probably non-diseases (→ C4-acylcarnitine is excluded from NBS programmes in several countries):
 - outpatient assessment, continue breast feeding
 - Confirm.: Acylcarnitines (plasma), OA (urine)
 - Neonatal Presentation: None
 - OA In EE:**Ethylmalonic acid, isovaleryl glycine**

Follow-up testing for elevated C-4

- *Possible diagnosis: isobutyryl-coA dehydrogenase deficiency(IBC D), (SCAD deficiency, MAD deficiency)*
- **Urine organic acids analysis - elevated isobutyrylglycine in IBCD**
- LACTIC, ALPHA-KG, ACONITIC, CITRIC, 4OH-HIPPURIC

- Urine organic acids analysis - **marked elevation of ethylmalonic and 2-methylsuccinic acids, butyrylglycine** (“classical” SCAD); **modest elevation** of ethylmalonic (“mild variant” SCAD); one or more of the following modestly elevated: ethylmalonic acid, adipic acid, glutaric acid, butyrylglycine, isobutyrylglycine, isovalerylglycine, hexanoylglycine, suberylglycine (MAD)

Mitochondrial β -oxidation




Table 1. The currently identified members of the human acyl-CoA dehydrogenase protein family with their primary metabolic function and optimal substrates.

| Gene | ACAD# | Protein name | Catabolic pathway | Optimal substrate | Structure |
|---------------|--------------|---|--------------------------|--------------------------|------------------------------|
| <i>ACADM</i> | ACAD1 | Medium-chain acyl-CoA dehydrogenase/MCAD | Fatty acids | C4:0-C12:0 | Soluble matrix homo-tetramer |
| <i>IVD</i> | ACAD2 | Isovaleryl-CoA dehydrogenase/IVD | Leucine | Isovaleryl-CoA | Soluble matrix homo-tetramer |
| <i>ACADs</i> | ACAD3 | Short-chain acyl-CoA dehydrogenase/SCAD | Fatty acids | C4:0-C6:0 | Soluble matrix homo-tetramer |
| <i>ACADL</i> | ACAD4 | Long-chain acyl-CoA dehydrogenase/LCAD | Fatty acids | C10:0-16:0 | Membrane bound homo-dimer |
| <i>GCD</i> | ACAD5 | Glutaryl-CoA dehydrogenase/GCD | Lysine/tryptophan | Glutaryl-CoA | Soluble matrix homo-tetramer |
| <i>ACADVL</i> | ACAD6 | Very-long-chain acyl-CoA dehydrogenase/VLCAD | Fatty acids | C12:0-C22:0 | Membrane-bound homo-dimer |
| <i>ACADSB</i> | ACAD7 | Short/branched-chain acyl-CoA dehydrogenase/SBCAD | Isoleucine | 2-Me-butyryl-CoA | Soluble matrix homo-tetramer |
| <i>ACAD8</i> | ACAD8 | Isobutyryl-CoA dehydrogenase/IBD | Valine | Isobutyryl-CoA | Soluble matrix homo-tetramer |
| <i>ACAD9</i> | ACAD9 | ACAD family member 9 | (Fatty acids) | ? | Membrane-bound homo-dimer |
| <i>ACAD10</i> | ACAD10 | ACAD family member 10 | N/A | N/A | |
| <i>ACAD11</i> | ACAD11 | ACAD family member 11 | N/A | N/A | |

Fatty acid oxidation defects

| Disorders | Primary metabolite in MS/MS | Confirmatory tests / follow-up | Findings in confirmatory tests |
|--|--|---|---|
| Carnitine acylcarnitine translocase (CACT) deficiency | ↑ C16–C18 acylcarnitines, ↓ Free carnitine | PACP, CK, glucose, NH ₃ | ↑ C16–C18 acylcarnitines on PACP; ↓ free carnitine, ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| Carnitine palmitoyl transferase type 1 (CPT-1) deficiency | ↓ C16–C18 acylcarnitines, ↕–↑ free carnitine | PACP, CK, glucose, NH ₃ | ↓ C16–C18 acylcarnitines on PACP; ↕–↑ free carnitine, ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| Carnitine palmitoyl transferase type 2 (CPT-2) deficiency | ↑ C16–C18 acylcarnitines, ↓ free carnitine | PACP, CK, glucose, NH ₃ | ↑ C16–C18 acylcarnitines on PACP; ↓ free carnitine, ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| Carnitine uptake/ transporter defect | ↓ C16–C18 acylcarnitines, ↓ free carnitine | PACP, urine carnitine, CK, glucose, NH ₃ | ↓ C16–C18 acylcarnitines on PACP; ↑ urine carnitine; ↓ free carnitine, ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| 3-Hydroxy long chain acyl-CoA dehydrogenase deficiency (LCHAD/MTP) | ↑ Long chain 3-hydroxy acylcarnitines | PACP, UOA, CK, glucose, NH ₃ | ↑ Long chain 3-hydroxy acylcarnitines on PACP; ↑ 3-OH dicarboxylic acids on UOA; ↑ CK, ↓ Glucose, ↑ NH ₃ on plasma |
| Medium chain acyl-CoA dehydrogenase (MCAD) deficiency | ↑ C8–C10 acylcarnitines | PACP, UOA, CK, glucose, NH ₃ | ↑ C8–C10 acylcarnitines on PACP; ↑ dicarboxylic acids, hexanoylglycine, phenylpropionylglycine and suberylglycine on UOA; ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| Multiple acyl-CoA dehydrogenase deficiency (MADD) or glutaric acidemia-type 2 | ↑ Multiple acylcarnitines | PACP, UOA, CK, glucose, NH ₃ | ↑ Multiple acylcarnitines on PACP; ↑ glutaric, ethylmalonic, dicarboxylic acids, hexanoylglycine, phenylpropionylglycine and suberylglycine on UOA; ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |
| Short chain acyl-CoA dehydrogenase deficiency (SCAD) | ↑ Butyrylcarnitine (C4) | PACP, UOA | ↑ Butyrylcarnitine on PACP; ↑ ethylmalonic, methylsuccinic, butyrylglycine on UOA |
| Very long chain acyl-CoA dehydrogenase deficiency (VLCAD) | ↑ C14, C14:1, C14:2 acylcarnitines, ↓ Free carnitine | PACP, CK, glucose, NH ₃ | ↑ Long chain acylcarnitines on PACP; ↑ CK, ↓ glucose, ↑ NH ₃ on plasma |

Acylcarnitines in FAO defects: Summary

- | Acylcarnitine species | Disorder to be considered |
|------------------------------|----------------------------------|
| • C0 | Transporter defect |
| • C4 | SCAD, MAD |
| • C5 (with C4) | MAD |
| • C6 (with C8; C10:1) | MCAD |
| • C8 | MCAD |
| • C10 (with C8, C10:1) | MCAD |
| • C10:1 (with C8) | MCAD |
| • C14:1 | VLCAD |

Acylcarnitines in FAO defects: Summary

- **Acylcarnitine species** **Disorder to be considered**
- **C14:1-OH (with C16-OH)** **LCHAD/TFP**
- **C16 (usually with C18:1)** **CPT-II, CAT**
- **C18:1 (with C16)** **CPT-II, CAT**
- **C16-OH** **LCHAD, TFP**
- **C18:1-OH (with C16-OH)** **LCHAD, TFP**
- **C16 Low (with C18:1)** **CPT-I**
- **C18:1 Low (with C16)** **CPT-I**

□ Assessment of acylcarnitine profile with MS/MS method is diagnostic:

❖ In urine GCMS, findings is nonspecific→

- **Dicarboxylic aciduria:** ↑ suberate, sebacate, adipate
- **Non ketosis:** ↓ A.A- β HB

❖ **PCD:**

- ↓ Co (Free carnitine)
- ↓ Long chains (↓ C16 - C18)

□ C16 (Hexadecanoyl carnitine)

□ C 18 (octadecanoyl carnitine)

❖ **CPT₁:**

- ↑ Co
- ↓ Long chains (↓ C16- C18)

❖ **SCAD:** ■ ↑ C₄ (Butyryl carnitine)
■ ↑ EM- M.S

❖ **MCAD:** ■ ↑ C₈ (octanoyl carnitine)
■ ↑ H.G, S.G

❖ **SCHAD:** ■ ↑ C₄OH (3-hydroxy butyryl carnitine)

❖ **VLCAD:** ■ ↑ C_{14:1} (tetradecenoyl carnitine)

| Analyte Abbreviation | Analyte Full name | Result (µM) | reference interval | pathologic border | Description |
|----------------------|---|-------------|--------------------|-------------------|-------------|
| Ala | Alanine | 136.56 | 83-332 | >467 | Normal |
| Arg | Arginine | 23.28 | 3.39-51.31 | <2.80, >62.07 | Normal |
| Cit | Citrulline | 14.80 | 4.4-27 | <3, >50 | Normal |
| Glu | Glutamic Acid | 403.36 | 172.2-645.1 | >723 | Normal |
| Gly | Glycine | 150.30 | 69.3-308.5 | >336.6 | Normal |
| Leu+Ile | Leucine+Isoleucine | 117.52 | 48-201 | >215 | Normal |
| Met | Methionine | 19.58 | 7.06-27.84 | <6.37, >34.25 | Normal |
| Orn | Ornithine | 87.66 | 48.55-182 | >202 | Normal |
| Phe | Phenylalanine | 46.91 | 25.21-79.94 | >119 | Normal |
| Pro | Proline | 147.82 | 81-374 | >404 | Normal |
| Tyr | Tyrosine | 676.00 | 40.1-267.6 | >296.4 | * |
| Val | Valine | 100.03 | 42.3-148 | >159 | Normal |
| C0 | Free Carnitine | 30.367 | 7.14-43.34 | <5.6, 48 | Normal |
| C2 | Acetylcarnitine | 31.255 | 5.92-40.68 | <3.95, >45.29 | normal |
| C3 | Propionylcarnitine | 1.956 | 0.37-4.30 | <0.2, >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.000 | <0.25 | >0.44 | Normal |
| C4 | Butyrylcarnitine | 1.764 | 0.085-0.7 | >0.97 | * |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.182 | <0.31 | >1.14 | Normal |
| C5 | Isovalerylcarnitine | 0.194 | <0.53 | >0.63 | Normal |
| C5:1 | Tiglylcarnitine | 0.121 | <0.074 | >0.23 | * |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.699 | <0.45 | >0.49 | * |
| C6 | Hexanoylcarnitine | 0.043 | <0.10 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.220 | <0.46 | >0.5 | Normal |
| C8 | Octanoylcarnitine | 0.056 | <0.10 | >0.38 | Normal |
| C8:1 | Octenoylcarnitine | 0.049 | <0.19 | >0.24 | Normal |
| C10 | Decanoylcarnitine | 0.073 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.063 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.019 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.087 | <0.146 | >0.26 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.060 | <0.09 | >0.15 | Normal |
| C14 | Tetradecanoylcarnitine | 0.180 | <0.36 | >0.58 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.086 | <0.13 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.014 | <0.025 | >0.042 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.008 | <0.016 | >0.02 | Normal |
| C16 | Hexadecanoylcarnitine | 2.718 | 0.32-5.22 | <0.23, >6.47 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.011 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.198 | <0.29 | >0.31 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.031 | <0.12 | >0.3 | Normal |
| C18 | Octadecanoylcarnitine | 0.756 | 0.17-1.56 | <0.14, >1.76 | Normal |
| C18:1 | Octadecenoylcarnitine | 1.244 | 0.27-2.32 | <0.23, >2.53 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.104 | 0.055-0.54 | <0.048, >0.62 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.014 | <0.03 | >0.11 | Normal |
| C18:2OH | Hydroxylinooleoylcarnitine | 0.007 | <0.07 | >0.14 | Normal |

| | | | | | |
|-------------|---|--------|-----------|---------------|--------|
| Ala | Alanine | 98.40 | <338 | >580 | Normal |
| Arg | Arginine | 31.96 | 2.45-43 | <1.27, >75 | Normal |
| Cit | Citrulline | 20.94 | 5.77-27 | <1.69, >60 | Normal |
| Glu | Glutamic Acid | 251.48 | <532 | >940 | Normal |
| Gly | Glycine | 93.71 | <307 | >417 | Normal |
| Leu+Ile | Leucine+Isoleucine | 92.51 | <201 | >252 | Normal |
| Met | Methionine | 16.24 | 6.97-22 | <4.90, >31 | Normal |
| Orn | Ornithine | 93.88 | <177 | >193 | Normal |
| Phe | Phenylalanine | 26.95 | <64 | >111 | Normal |
| Pro | Proline | 142.28 | <351 | >371 | Normal |
| Tyr | Tyrosine | 552.69 | <120 | >140 | * |
| Val | Valine | 73.57 | <131 | >171 | Normal |
| C0 | Free Carnitine | 27.470 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 8.714 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 0.548 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.071 | <0.17 | >0.38 | Normal |
| C4 | Butyrylcarnitine | 1.702 | <0.49 | >0.78 | * |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.124 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.195 | <0.39 | >0.57 | Normal |
| C5-1 | Tiglylcarnitine | 0.157 | <0.08 | >0.33 | * |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.288 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.053 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 0.262 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.054 | <0.10 | >0.37 | Normal |
| C8-1 | Octenoylcarnitine | 0.104 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.076 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.078 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.026 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.072 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.035 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.098 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.041 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienylcarnitine | 0.014 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.004 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.671 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.005 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.027 | <0.31 | >0.32 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.030 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.390 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.532 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.185 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.008 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.006 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.003 | <0/022 | >0/063 | Normal |



بیمارستان مرکز طبی کودکان - دکتر حسن اهری

Children's Medical Center

END OF KESHAVARZ BLVD.-DR.GHARIB ST. بیمارستان دکتر حسن اهری انتهای بلوار کشاورز خیابان دکتر قریب ۳-۹۸۱-۶۶۹۲

| | | | | |
|------------------------------|------------------------------|-----------------|-------------------------------|--------------------------------|
| شماره آزمایشگاه : L011102405 | نام : محمد علی تکین فر | جنس : مرد | OPD | تاریخ پذیرش : ۱۴۰۱/۱۱/۰۴ ۱۲:۵۸ |
| کد برگه : ۲۵۸۵۰۰۲ | نام پدر : پیام | سن : ۳۹ روز | تاریخ جواب : ۱۴۰۱/۱۱/۱۲ ۰۹:۰۱ | |
| کد پذیرش : ۵۹۳۷۵۶۴ | پزشک معالج : دکتر طالع - علی | نوع بیمه : آزاد | تاریخ چاپ : ۱۴۰۲/۰۶/۰۶ ۱۴:۳۹ | |

HPLC(plasma)

| Test | Result | Unit | Reference Value |
|--------------------|--------------|--------|-----------------|
| Aspartic Acid | 7.3 | uMol/L | 0-20 |
| Glutamic Acid | 75.3 | uMol/L | 10-120 |
| Asparagine | 42.4 | uMol/L | 24-60 |
| Serine | 145.1 | uMol/L | 60-200 |
| Glutamine | 653.0 | uMol/L | 396-746 |
| Histidine | 79.5 | uMol/L | 50-130 |
| Glycine | 179.8 | uMol/L | 140-490 |
| Threonine | 196.1 | uMol/L | 40-240 |
| Citrulline | 31.0 | uMol/L | 8-47 |
| Arginine | 69.0 | uMol/L | 40-160 |
| Taurine | 49.0 | uMol/L | 19-216 |
| Alanine | 226.7 | uMol/L | 240-600 |
| Tyrosine | 654.7 | uMol/L | 30-120 |
| α-Aminobutric Acid | 11.9 | uMol/L | 6-38 |
| Tryptophane | 54.9 | uMol/L | 15-73 |
| Methionine | 20.0 | uMol/L | 6-49 |
| Valin | 152.6 | uMol/L | 140-350 |
| Phenylalanine | 44.9 | uMol/L | 30-80 |
| Isolucine | 73.5 | uMol/L | 30-130 |
| leucine | 110.6 | uMol/L | 60-230 |
| Ornitine | 81.0 | uMol/L | 20-135 |
| Lysine | 126.8 | uMol/L | 80-250 |

پلازما اینکتر : Comment

* Rechecked



Urine Organic Acid Analysis

Growth And Development Research center
Iran Metabolic Center

Document Number: HD-IMC-
LA-RS-01-110516

date:01/11/08

Name of Lab Center: Iran Metabolic Center

Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran Telephone 021-61472434 Fax: 66949662

Patient's name: Mohamadali Neginfar

Lab number:2405

Patient's ID:012011105000018014040516

Sample type: urine

Gender: male

age:18d

Physician/referred by: CMC

Reception Date:01/11/05

Reporting date: 01/11/08

Result:

| Abnormal Compound | Cut off | measure |
|-----------------------------|---------|----------|
| Homovanillic acid | 42.35% | 104.58% |
| Vanilmandelic acid | 156.72% | 210.30% |
| Adipic acid | 13.00% | 21.48% |
| Lactic acid | 6.70% | 16.62% |
| 4-Hydroxyphenyllactic acid | 12.51% | 2749.88% |
| Ethylmalonic acid | 7.45% | 182.81% |
| Pyruvic acid-oxime | 32.61% | 179.46% |
| Phenyllactic acid | 5.79% | 13.15% |
| Methylsuccinic acid | 8.62% | 56.36% |
| 4-Hydroxyphenylacetic acid | 139.99% | 771.84% |
| Phenylpyruvic acid-oxime | 0.50% | 2.26% |
| 4-Hydroxyphenylpyruvic acid | 1.90% | 785.61% |

Comment:

➤ TFP
➤ LCHAD → ↑ C_{16OH}- C_{18OH}

C_{16OH}: (3-hydroxyhexadecanoyl carnition)

C_{18OH}: (3-hydroxyoctadecanoyl carnitine)

❖ CPT₂
❖ CACT → ↑ C₁₆- C_{18:1}

C₁₆: Hexadecanoyl carnitine

C_{18:1}: octadecenoyl carnitine

Elevated C0

- Diagn.: CPT1 deficiency: $\uparrow C0/(C16 + C18)$
- Confirm.: Acylcarnitines (plasma), carnitine status
- **Secondary** to rhabdomyolysis

Very low C0

- **DD**: Carnitine transporter deficiency ,organic acidurias, prematurity; if FTR normal: test mother for carnitine deficiency
- Confirm.: OA urine, carnitine status, fractional tubular re-absorption (**FTR**) of carnitine
- **Plasma acylcarnitine analysis - low C0 (usually <10**
- **μM); low acylcarnitine signals generally**
- **Urine organic acids analysis - non-specific findings;**
- **absence of dicarboxylic acids.**

Carnitine Uptake/Transport Deficiency (CUD)

- **Low C0** (free carnitine)
- **C3 (propionyl carnitine) + C16 (palmitoyl carnitine) < 2**
- *Maternal CUD* - In some newborns, the low free carnitine is reflective of maternal CUD.
- **C0+C2+C3+C16+C18:1/Cit** **informative marker**
- **Low C0** : medications including **valproate**, other...
- **Secondary** carnitine deficiencies,
 - insufficient dietary intake,
 - Renal tubulopathy,

| | | | | | |
|-------------|--|--------|------------|---------------|--------|
| Pro | Proline | 130.09 | <3/4 | >404 | Normal |
| Tyr | Tyrosine | 127.58 | <292.74 | >336.58 | Normal |
| Val | Valine | 94.10 | <131 | >143 | Normal |
| C0 | Free Carnitine | 3.334 | 7.14-43.34 | <5.6, 48 | * |
| C2 | Acetylcarnitine | 0.825 | 5.92-40.68 | <3.95, >45.29 | * |
| C3 | Propionylcarnitine | 0.090 | 0.37-4.30 | <0.31, >5 | * |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.026 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.025 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | ethylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.027 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.039 | <0.39 | >0.47 | Normal |
| C5:1 | Tiglylcarnitine | 0.007 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoylcarnitine | 0.050 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.016 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutaryl carnitine | 0.216 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.013 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.038 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.020 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.008 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.009 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.009 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.004 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.009 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.007 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.003 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.000 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.042 | 0.41-6.09 | <0.33, >7.13 | * |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.002 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.004 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.001 | <0.11 | >0.134 | Normal |
| C18 | Octadecanoylcarnitine | 0.031 | 0.19-1.71 | <0.16, >1.89 | * |
| C18:1 | Octadecenoylcarnitine | 0.080 | 0.32-2.33 | <0.27, >2.55 | * |
| C18:2 | Octadecadienylcarnitine | 0.012 | 0.059-0.56 | <0.05, >0.66 | * |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.002 | <0.07 | >0.14 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.002 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.001 | <0/022 | >0/11 | Normal |

Search, Add, Control, Select, 02, Control, Micro, Document, English, [Navigation icons]



| | | | | | |
|-------------|--|--------|------------|---------------|--------|
| Pro | Proline | 130.09 | <3/4 | >404 | Normal |
| Tyr | Tyrosine | 127.58 | <292.74 | >336.58 | Normal |
| Val | Valine | 94.10 | <131 | >143 | Normal |
| C0 | Free Carnitine | 3.334 | 7.14-43.34 | <5.6, 48 | * |
| C2 | Acetylcarnitine | 0.825 | 5.92-40.68 | <3.95, >45.29 | * |
| C3 | Propionylcarnitine | 0.090 | 0.37-4.30 | <0.31, >5 | * |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.026 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.025 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | ethylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.027 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.039 | <0.39 | >0.47 | Normal |
| C5:1 | Tiglylcarnitine | 0.007 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutarylcarnitine & Hydroxyhexanoylcarnitine | 0.050 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.016 | <0.11 | >0.14 | Normal |
| C6DC | Methylglutarylcarnitine | 0.216 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.013 | <0.10 | >0.3 | Normal |
| C8:1 | Octenoylcarnitine | 0.038 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.020 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.008 | <0.11 | >0.21 | Normal |
| C10:2 | Decadienylcarnitine | 0.009 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.009 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.004 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.009 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.007 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienylcarnitine | 0.003 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.000 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.042 | 0.41-6.09 | <0.33, >7.13 | * |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.002 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.004 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.001 | <0.11 | >0.134 | Normal |
| C18 | Octadecanoylcarnitine | 0.031 | 0.19-1.71 | <0.16, >1.89 | * |
| C18:1 | Octadecenoylcarnitine | 0.080 | 0.32-2.33 | <0.27, >2.55 | * |
| C18:2 | Octadecadienylcarnitine | 0.012 | 0.059-0.56 | <0.05, >0.66 | * |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.002 | <0.07 | >0.14 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.002 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.001 | <0/022 | >0/11 | Normal |

C 2

(Acetylcarnitine)

- Elevate in: Carnitine supplementation or **ketosis** (deficiency if low)
- HMG CoA synthase deficiency (3-hydroxy-3 methyl glutary CoA synthase deficiency)
- Conf: plasma AC, in organic acid **crotonylglycine/4 hydroxy- 6 methyl-2-pyrone**
- **Low C2** in CUD/Ethylmalonic Encephalopathy
- ,CPT2,MCAD

Carnitine Palmitoyl Transferase Type I Deficiency (CPT IA)

- **Primary High Markers**
- Elevated C0
- **Elevated C0 (Free Carnitine)/C16 (palmitoyl carnitine) + C18 (octadecanoyl carnitine) ratio**
- **Primary Low Markers**
- **Low C16 (palmitoyl carnitine)**
- **Low C18 (octadecanoyl carnitine)**
- Low C18:1
- Low C18:2
- **OA: unremarkable. No specific diagnostic metabolites.**

Carnitine Palmitoyl Transferase Type II Deficiency (CPT II)

- **Primary Markers**
- Elevated C16 (palmitoyl carnitine)
- Elevated C18
- **Informative Markers**
- Elevated C12
- Elevated C16OH
- Elevated C18:1 (oleyl carnitine)
- **OA: either normal, or showing dicarboxylic aciduria and 3-hydroxydicarboxylic aciduria with reduced ketones when fasting. No specific diagnostic metabolites.**

Carnitine/Acylcarnitine Translocase Deficiency (CACT)

- **Primary Markers**
- Elevated C16 (palmitoyl carnitine)
- **Elevated C18 (octadecanoyl carnitine)**
- **Informative Markers**
- Elevated C12
- Elevated C16OH
- Elevated C18:1 (oleyl carnitine)

Elevated long-chain acylcarnitines

- DD: ↑ C16, C18; low C0: carnitine translocase or CPT2 deficiency
- ↑ C14:1, C14, C14:1/C4, C14:1/C12:1, etc.: VLCAD deficiency
- ↑ C16OH, C18:1OH LCHAD/MTP deficiency
- C12-OH 3-Hydroxy dodecanoyl- LCHAD/TFP deficiency/C14-OH
- Confirm: Acylcarnitines (plasma), OA (urine), carnitine status

Very Long Chain Acyl Co-A Dehydrogenase Deficiency (VLCAD)

- **Primary Markers**
- Elevated C14:1 (tetradecenoyl carnitine)
- **Elevated C14:1/C2 ratio**
- **High Secondary Markers**
- Elevated C12 (dodecanoyl carnitine)
- Elevated C12:1 (dodecenoyl carnitine)
- Elevated C14 (tetradecanoyl carnitine)
- Elevated C14:2 (tetradecadienoyl carnitine)
- Elevated C16 (palmitoyl carnitine)
- **Urine organic acids analysis** - either normal, or showing
- dicarboxylic aciduria with reduced ketones when fasting

Long Chain 3-OH Acyl Co-A Dehydrogenase Deficiency (LCHAD) and Trifunctional Protein Deficiency (TFP)

- Abnormal Screen Result:
- **Primary Marker**
- Elevated C16-OH (3-OH palmitoyl carnitine)
- **Secondary Markers**
- Elevated C14:1 (tetradecenoyl carnitine)
- Elevated C14 (tetradecanoyl carnitine)
- Elevated C18 (octadecanoyl carnitine)
- Elevated C18:1-OH (3-OH oleyl carnitine)
- C14-OH/C12-OH
- **OA:** either normal, or showing **dicarboxylic** aciduria and **3-hydroxydicarboxylic** aciduria with reduced ketones when fasting. No specific diagnostic
- metabolites for LCHAD; 3-OH-monocarboxylic acids might accumulate in TFP deficiency

Malonic aciduria /Medium/Short Chain 3-OH acyl CoA Dehydrogenase Deficiency (M/SCHAD)

- Metab.: \uparrow C3DC, C4OH
- Elevated C3DC (malonyl carnitine) + C4OH (3-OH butyryl carnitine)
- Elevated C3DC (malonyl carnitine) + C4OH (3-OH butyryl carnitine)/C10 (decanoyl carnitine) ratio
- C10-OH
- OA:Malonic acid
- C4OH In 1: SCHAD OA:3 Hydroxy Glutaric acid
- 2:3 hydroxyisobutyryl coa hydrolase deficiency

| | | | | | |
|-------------|---|--------|-----------|---------------|--------|
| Gly | Glycine | 88.10 | <307 | >417 | Normal |
| Leu+Ile | Leucine+Isoleucine | 82.06 | <201 | >252 | Normal |
| Met | Methionine | 9.08 | 6.97-22 | <4.90, >31 | Normal |
| Orn | Ornithine | 66.67 | <177 | >193 | Normal |
| Phe | Phenylalanine | 34.33 | <64 | >111 | Normal |
| Pro | Proline | 58.87 | <351 | >371 | Normal |
| Tyr | Tyrosine | 47.46 | <120 | >140 | Normal |
| Val | Valine | 95.68 | <131 | >171 | Normal |
| C0 | Free Carnitine | 37.553 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 9.407 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 2.515 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 1.147 | <0.17 | >0.38 | * |
| C4 | Butyrylcarnitine | 0.235 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.197 | <0.19 | >0.78 | * |
| C5 | Isovalerylcarnitine | 0.166 | <0.39 | >0.57 | Normal |
| C5:1 | Tiglylcarnitine | 0.049 | <0.08 | >0.33 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.196 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.051 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 0.215 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.046 | <0.10 | >0.37 | Normal |
| C8:1 | Octenoylcarnitine | 0.061 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.055 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.044 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.022 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.027 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.020 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.067 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.032 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.012 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.004 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.560 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.007 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.034 | <0.31 | >0.32 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.031 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.523 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.783 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.254 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.015 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.010 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.006 | <0/022 | >0/063 | Normal |

| | | | | | |
|-------------|---|--------|-----------|---------------|--------|
| Gly | Glycine | 88.15 | <50/ | >41/ | Normal |
| Leu+Ile | Leucine+Isoleucine | 80.14 | <201 | >252 | Normal |
| Met | Methionine | 9.27 | 6.97-22 | <4.90, >31 | Normal |
| Orn | Ornithine | 60.58 | <177 | >193 | Normal |
| Phe | Phenylalanine | 29.07 | <64 | >111 | Normal |
| Pro | Proline | 63.32 | <351 | >371 | Normal |
| Tyr | Tyrosine | 41.49 | <120 | >140 | Normal |
| Val | Valine | 99.22 | <131 | >171 | Normal |
| C0 | Free Carnitine | 39.927 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 14.314 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 2.280 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 1.188 | <0.17 | >0.38 | * |
| C4 | Butyrylcarnitine | 0.250 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.183 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.152 | <0.39 | >0.57 | Normal |
| C5:1 | Tiglylcarnitine | 0.032 | <0.08 | >0.33 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.203 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.047 | <0.11 | >0.18 | Normal |
| C6DC | Methylglutaryl carnitine | 0.208 | <0.52 | >0.56 | Normal |
| C8 | Octanoylcarnitine | 0.050 | <0.10 | >0.37 | Normal |
| C8:1 | Octenoylcarnitine | 0.062 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.067 | <0.132 | >0.190 | Normal |
| C10:1 | Decenoylcarnitine | 0.051 | <0.10 | >0.18 | Normal |
| C10:2 | Decadienylcarnitine | 0.018 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.030 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.015 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.076 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.037 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienylcarnitine | 0.014 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.003 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.690 | 0.48-6.09 | <0.28, >8.16 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.004 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.038 | <0.31 | >0.32 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.054 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.756 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 1.334 | 0.32-2.17 | <0.24, >2.61 | Normal |
| C18:2 | Octadecadienylcarnitine | 0.397 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.016 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.014 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.003 | <0/022 | >0/063 | Normal |

| Ac | Compound | Value | Ref Range | Ref Range | Normal |
|--------------|---|---------|-----------|----------------|--------|
| Gly | Glycine | 153.00 | <417 | >632 | Normal |
| Leu+Ile | Leucine+Isoleucine | 59.60 | <170 | >224 | Normal |
| Met | Methionine | 12.70 | 9.0-32 | <6.39 , >45 | Normal |
| Orn | Ornithine | 53.00 | <133 | >148 | Normal |
| Phe | Phenylalanine | 29.20 | <69 | >129 | Normal |
| Pro | Proline | 61.90 | <292 | >314 | Normal |
| Tyr | Tyrosine | 38.20 | <264 | >140 | Normal |
| Val | Valine | 80.90 | <156 | >199 | Normal |
| C0 | Free Carnitine | 25.90 | 8/0-40 | <4.68 , >57 | Normal |
| C2 | Acetylcarnitine | 13.90 | 7-38 | <5 , >40 | Normal |
| C3 | Propionylcarnitine | 1.09 | 0.3-4/6 | <0.21 , >6 | Normal |
| C3DC & C8OH | Malonylcarnitine & 3-Hydroxyoctanoylcarnitine | 0.00 | <0/05 | >0/15 | Normal |
| C4 | Butyrylcarnitine | 0.22 | <0.55 | >0/862 | Normal |
| C4OH | Hydroxybutyrylcarnitine | 1.13 | <0.3 | >0.64 | * |
| C4DC | Methylmalonylcarnitine | 0.06 | <0/25 | >0.5 | Normal |
| C5 | Isovalerylcarnitine | 0.08 | <0.36 | >0.54 | Normal |
| C5DC & C10OH | Glutaryl carnitine & 3-Hydroxydecanoylcarnitine | 0.10 | <0/15 | >0.16 | Normal |
| C5:1 | Tiglylcarnitine | 0.01 | <0.03 | >0.143 | Normal |
| C5OH | Hydroxyisovalerylcarnitine | 0.10 | <0/27 | >0.6 | Normal |
| C6 | Hexanoylcarnitine | 0.09 | <0.09 | >0.16 | Normal |
| C6DC | Adipoylcarnitine | 0.03 | <0.05 | >0.087 | Normal |
| C8 | Octanoylcarnitine | 0.06 | <0.08 | >0.34 | Normal |
| C8:1 | Octenoylcarnitine | 0.06 | <0/18 | >0.19 | Normal |
| C10 | Decanoylcarnitine | 0.04 | <0.14 | >0.18 | Normal |
| C10:2 | Decadienoylcarnitine | 0.02 | <0.03 | >0.07 | Normal |
| C10:1 | Decenoylcarnitine | 0.01 | <0.12 | >0.22 | Normal |
| C12 | Dodecanoylcarnitine | 0.07 | <0.3 | >0.75 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.05 | <0.2 | >0.39 | Normal |
| C14 | Tetradecanoylcarnitine | 0.05 | <0/35 | >0.64 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.00 | <0.05 | >0.11 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.06 | <0.17 | >0.36 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.00 | <0/03 | >0/04 | Normal |
| C16 | Hexadecanoylcarnitine | 0.56 | 0/55-7/08 | <0/324 , >10 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.03 | <0/47 | >0.51 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.03 | <0/14 | >0.19 | Normal |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.00 | <0.05 | >0.2 | Normal |
| C18 | Octadecanoylcarnitine | 0.48 | 0.22-1/67 | <0.142 , >2.18 | Normal |
| C18:2 | Octadecadienoylcarnitine | 0.24 | 0/07-0/68 | <0.046 , >1.08 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.73 | 0/35-2/5 | <0.156 , >3.09 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.0216 | <0/09 | >0/1 | Normal |
| C18:1OH | Hydroxyoleoylcarnitine | 0.00704 | <0/04 | >0.07 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.00704 | <0/03 | >0.08 | Normal |

Pre-analytical aspects C8

Factors affecting the screening results

- C8 concentrations **decrease** slightly with increasing birth weight and in general, males have slightly higher C8 concentrations than females;
- **Potential for false negatives** :
- Transfusions could result in a false negative result, At least **72 hours** is recommended

Dextrose administration in a sick neonate with MCADD prior to blood collection may reduce octanoylcarnitine levels.

It is known that **C8 falls** in older infants (after approximately **1 month of age**)

False positive C8

- **Premature/sick infants** - Some special formulas and breast milk fortifiers fed to premature/sick infants contain **medium chain triglycerides (MCT)** as the primary fat source. These feedings may cause **false elevations** of some acyl carnitines analyzed in MCAD screening, particularly C8, C10:1 and C8/C10.
- **Hypoxia/stress induced lipolysis/riboflavin deficiency or deficient mother/valproate therapy/mitochondrial myopathy/** Physiological stress / Early sampling , contamination
- **MAD DEFICIENCY:**C4,C5,C6,C8,C10,C12,C14,C14:1

Elevated medium-chain acylcarnitines

- Diagn.: **MCAD** deficiency: ↑ C8, C8/C2, C8/C12
- **Abnormal Screen Result: Primary Markers**
- **Elevated C8 (octanoyl carnitine)**
- Elevated C10 (decanoyl carnitine)
- Elevated C10:1 (decenoyl carnitine)
- **Secondary Markers**
- **Elevated C6 (hexanoyl carnitine)**
- Elevated C8/C10
- Confirm.: Acylcarnitines (plasma), OA
- (urine- elevated **hexanoylglycine** and **suberylglycine**, often with **5-OH-hexanoic acid**, also with **dicarboxylic acids** when fasting. Variants can be normal)

| Urn | Urnitine | 86.17 | <177 | >195 | Normal |
|-------------|---|--------|-----------|---------------|--------|
| Phe | Phenylalanine | 33.31 | <64 | >111 | Normal |
| Pro | Proline | 160.03 | <351 | >371 | Normal |
| Tyr | Tyrosine | 51.21 | <120 | >140 | Normal |
| Val | Valine | 57.62 | <131 | >171 | Normal |
| C0 | Free Carnitine | 23.499 | 7.77-42 | <4.38, >58 | Normal |
| C2 | Acetylcarnitine | 6.296 | 6.2-40.5 | <4.3, >44.8 | Normal |
| C3 | Propionylcarnitine | 0.519 | 0.38-4.24 | <0.27, >5.82 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.062 | <0.17 | >0.38 | Normal |
| C4 | Butyrylcarnitine | 0.128 | <0.49 | >0.78 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.154 | <0.19 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.078 | <0.39 | >0.57 | Normal |
| C5:1 | Tiglylcarnitine | 0.004 | <0.08 | >0.33 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.118 | <0.41 | >0.45 | Normal |
| C6 | Hexanoylcarnitine | 0.864 | <0.11 | >0.18 | * |
| C6DC | Methylglutaryl carnitine | 0.923 | <0.52 | >0.56 | * |
| C8 | Octanoylcarnitine | 2.557 | <0.10 | >0.37 | * |
| C8:1 | Octenoylcarnitine | 0.171 | <0.18 | >0.21 | Normal |
| C10 | Decanoylcarnitine | 0.169 | <0.132 | >0.190 | * |
| C10:1 | Decenoylcarnitine | 0.820 | <0.10 | >0.18 | * |
| C10:2 | Decadienylcarnitine | 0.039 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.019 | <0.16 | >0.37 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.012 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.040 | <0/39 | >0.7 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.014 | <0.12 | >0.25 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.009 | <0/02 | >0.11 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.003 | <0/01 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.400 | 0.48-6.09 | <0.28, >8.16 | * |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.004 | <0.04 | >0.14 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.015 | <0.31 | >0.32 | Normal |
| C16:1OH | Hydroxyhexadecenoylcarnitine | 0.018 | <0/11 | >0/178 | Normal |
| C18 | Octadecanoylcarnitine | 0.284 | 0.21-1.71 | <0.14, >2.17 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.287 | 0.32-2.17 | <0.24, >2.61 | * |
| C18:2 | Octadecadienylcarnitine | 0.136 | 0.06-0.6 | <0.057, >0.65 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.004 | <0.07 | >0.17 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.004 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.003 | <0/022 | >0/063 | Normal |



Edit Convert Sign

Find text or tools



| | | | | | |
|-------------|---|--------|------------|---------------|--------|
| Val | Valine | 58.78 | <131 | >143 | Normal |
| C0 | Free Carnitine | 21.936 | 7.14-43.34 | <5.6, 48 | Normal |
| C2 | Acetylcarnitine | 6.391 | 5.92-40.68 | <3.95, >45.29 | normal |
| C3 | Propionylcarnitine | 0.759 | 0.37-4.30 | <0.31 , >5 | Normal |
| C3DC&C4OH | Malonylcarnitine & Hydroxybutyrylcarnitine | 0.032 | <0.2 | >0.31 | Normal |
| C4 | Butyrylcarnitine | 0.115 | <0.49 | >0.67 | Normal |
| C4DC & C5OH | Methylmalonylcarnitine & Hydroxyisovalerylcarnitine | 0.125 | <0.27 | >0.78 | Normal |
| C5 | Isovalerylcarnitine | 0.112 | <0.39 | >0.47 | Normal |
| C5:1 | Tiglylcarnitine | 0.012 | <0.08 | >0.204 | Normal |
| C5DC & C6OH | Glutaryl carnitine & Hydroxyhexanoyl carnitine | 0.108 | <0.49 | >0.58 | Normal |
| C6 | Hexanoylcarnitine | 0.572 | <0.11 | >0.14 | * |
| C6DC | Methylglutaryl carnitine | 0.641 | <0.52 | >0.56 | * |
| C8 | Octanoylcarnitine | 1.520 | <0.10 | >0.3 | * |
| C8:1 | Octenoylcarnitine | 0.073 | <0.19 | >0.22 | Normal |
| C10 | Decanoylcarnitine | 0.099 | <0.139 | >0.16 | Normal |
| C10:1 | Decenoylcarnitine | 0.398 | <0.11 | >0.21 | * |
| C10:2 | Decadienyl carnitine | 0.021 | <0.08 | >0.12 | Normal |
| C12 | Dodecanoylcarnitine | 0.021 | <0.16 | >0.32 | Normal |
| C12:1 | Dodecenoylcarnitine | 0.010 | <0.27 | >0.5 | Normal |
| C14 | Tetradecanoylcarnitine | 0.038 | <0/389 | >0.592 | Normal |
| C14:1 | Tetradecenoylcarnitine | 0.013 | <0.13 | >0.24 | Normal |
| C14:2 | Tetradecadienoylcarnitine | 0.009 | <0.026 | >0.041 | Normal |
| C14OH | Hydroxytetradecanoylcarnitine | 0.002 | <0/016 | >0/02 | Normal |
| C16 | Hexadecanoylcarnitine | 0.404 | 0.41-6.09 | <0.33 , >7.13 | * |
| C16OH | Hydroxyhexadecanoylcarnitine | 0.003 | <0.04 | >0.1 | Normal |
| C16:1 | Hexadecenoylcarnitine | 0.012 | <0/31 | >0/34 | Normal |
| C16:1OH | Hedroxyhexadecenoylcarnitine | 0.020 | <0.11 | >0.134 | Normal |
| C18 | Octadecanoylcarnitine | 0.222 | 0.19-1.71 | <0.16 , >1.89 | Normal |
| C18:1 | Octadecenoylcarnitine | 0.280 | 0.32-2.33 | <0.27 , >2.55 | * |
| C18:2 | Octadecadienyl carnitine | 0.160 | 0.059-0.56 | <0.05 , >0.66 | Normal |
| C18:1OH | Hydroxyoctadecenoylcarnitine | 0.004 | <0.07 | >0.14 | Normal |
| C18:2OH | Hydroxylinoleoylcarnitine | 0.006 | <0.022 | >0.024 | Normal |
| C18OH | Hydroxystearoylcarnitine | 0.002 | <0/022 | >0/11 | Normal |

| | | |
|---|--|---|
|  | <h2 style="margin: 0;">Urine Organic Acid Analysis</h2> <p style="margin: 0;">Growth And Development Research center Iran Metabolic Center</p> | <p>Document Number: HD-IMC-LA-RS-01-021626</p> <p>date:01/02/17</p> |
|---|--|---|

Name of Lab Center: Iran Metabolic Center
Address and Telephone Number of Lab Center: Growth and Development Research center Pediatrics Center of Excellence, Children's Medical center ,62 Dr.Qarib St, Keshavarz Blvd, Tehran
 Telephone 021-61472434 Fax: 66949662

| | | |
|-------------------------------|-------------------------|---------------------------------------|
| Patient's name: Karnia Maleki | Lab number:7794 | Patient's ID:012010217000210014041626 |
| Sample type: urine | Gender: male | age:2m, 10d |
| Physician/referred by: CMC | Reception Date:01/02/17 | Reporting date: 01/02/17 |

Result:

| Abnormal Compound | Cut off | measure |
|-------------------|---------|---------|
| Suberic acid | 11.51% | 32.51% |
| Octenedioic acid | 8.37% | 12.06% |

Comment:

The urine organic acid analysis shows increased level of dicarboxylic acids that based on previous result of patient, suspected diagnosis is Medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency. Confirmation of disease with genetic testing is recommended.

Medium Chain Ketoacyl CoA Thiolase Deficiency (MCAT)

- Abnormal Screen Result: Elevated **C8** (octanoyl carnitine)
- **C8-OH**
- **C6**
- **Dienoyl Co-A Reductase Deficiency (DE RED)**
- Elevated **C10:2** (decadienoyl carnitine)
- **C10:2/C10**

C8:1(L-Octenoyl carnitine)

- C8:1(Octanoylcarnitine)is detected in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. MCAD is characterized by an intolerance to prolonged fasting, recurrent episodes of hypoglycemic coma with medium-chain dicarboxylic aciduria, impaired ketogenesis, and low plasma and tissue carnitine levels .L-Octanoylcarnitine is also found to be associated with celiac disease and glutaric aciduria II

Glutaric Aciduria Type II (GA II)

(C4– C18)

- multiple acyl Co-A dehydrogenase deficiency (MADD)
- **Primary Markers**
- Elevated C4 (butyryl carnitine)
- Elevated C5 (isovaleryl carnitine)
- **Secondary Markers**
- Elevated C6 (hexanoyl carnitine)
- Elevated C8 (octanoyl carnitine)
- Elevated C10 (decanoyl carnitine)
- Elevated C10:1
- Elevated C12
- Elevated C12:1
- Elevated C14
- **Elevated C14:1 (tetradecenoyl carnitine)**
- Elevated C16OH
- Elevated C5DC

3/C) Mitochondrial disorders:

- ❖ There is not any specific finding in acyl carnitine profile
 - ❖ High blood level of:
 - Lactate
 - L/P ratio
 - ❖ Metabolic acidosis
-
- U.GCMS: increased level of:
 - Lactate
 - 3-hydroxybutyrate
 - Acetoacetate
 - Fumarate
 - Succinate
 - Malate
 - 2- ketoglutarate

Galactose (Gal) and galactose metabolites

- **Findings:** – **Galactose** (plasma, dried blood spots); pathological if > 10 mg/dl (0.55 mM)
- – **Galactose-1-phosphate** (erythrocytes); pathological if > 0.5 mg/dl (19 μ M)
- – **Galactitol** (urine); pathological if > 10 mmol/mol creatinine
- – Enzyme studies (erythrocytes): GALT, galactokinase, epimerase
- – Mutation studies (EDTA whole blood)

Pre-analytical aspects

- Galactosemia
- *Measurement of blood spot galactose-1-phosphate-uridyl-transferase (GAL-1-PUT)*
- *Thin-layer chromatography of sugars (galactose) using dried blood spots*
- *Measurement of blood spot galactose-1-phosphate (GALP)*

Galactosaemia

- Method: Gal-1-P uridyltransferase (**GALT**) activity; quantitation of galactose (Gal) and Gal-1-P (either in parallel or as second tier tests; in GALT and UDP-Gal epimerase [GALE] deficiencies almost all galactose [$> 90\%$] is Gal-1-P).
- DD: **↓ GALT** activity: classical galactosaemia (GALT deficiency)
- **↑ Gal**: inborn errors of Gal metabolism : GALT/GALE/GALK deficiencies);
- **liver failure** (various causes); **open ductus venosus arantii**

- GALT activity may be **false normal** after erythrocyte (exchange) **transfusion**. Exposure of test card to **humid heat** may cause denaturation of enzymes and consecutively a **false positive result for GALT activity**
- **Abnormal Screen Result: Elevated total galactose with low GALT: at risk for classical galactosemia.**
- **Normal total galactose with very low GALT: at risk for Duarte galactosemia, or at risk for classical galactosemia, if infant on non-lactose feeding at time of screening.**
- **Elevated total galactose with normal GALT: at risk for GALK or GALE deficiency.**
- Repeat screening for galactosemia should be done **120 days** after the last transfusion.

- If GALT is normal in the initial specimen, repeat galactosemia screening as soon as possible. **NO NEED TO STOP BREAST FEEDING OR CHANGE FORMULA TYPE at this time.**
- Neonatal Presentation: GALT - hypoglycemia, jaundice, sepsis, failure to thrive
- Duarte variant galactosemia - None
- GALK - None
- GALE - Usually none

Thanks

